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A B S T R A C T
Background
Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially
during the first or second pregnancy. To reduce these effects, theWorldHealthOrganization recommends that pregnant women living in
malaria endemic areas sleep under insecticide-treated bednets, are treated for malaria illness and anaemia, and receive chemoprevention
with an effective antimalarial drug during the second and third trimesters.
Objectives
To assess the effects of malaria chemoprevention given to pregnant women living in malaria endemic areas on substantive maternal
and infant health outcomes. We also summarised the effects of intermittent preventive treatment with sulfadoxine-pyrimethamine (SP)
alone, and preventive regimens for Plasmodium vivax.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and reference
lists up to 1 June 2014.
Selection criteria
Randomized controlled trials (RCTs) and quasi-RCTs of any antimalarial drug regimen for preventingmalaria in pregnant women living
in malaria-endemic areas compared to placebo or no intervention. In the mother, we sought outcomes that included mortality, severe
anaemia, and severe malaria; anaemia, haemoglobin values, and malaria episodes; indicators of malaria infection, and adverse events.
In the baby, we sought foetal loss, perinatal, neonatal and infant mortality; preterm birth and birthweight measures; and indicators of
malaria infection. We included regimens that were known to be effective against the malaria parasite at the time but may no longer be
used because of parasite drug resistance.
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Data collection and analysis
Two review authors applied inclusion criteria, assessed risk of bias and extracted data. Dichotomous outcomes were compared using
risk ratios (RR), and continuous outcomes using mean differences (MD); both are presented with 95% confidence intervals (CI). We
assessed the quality of evidence using the GRADE approach.
Main results
Seventeen trials enrolling 14,481 pregnant women met our inclusion criteria. These trials were conducted between 1957 and 2008, in
Nigeria (three trials), The Gambia (three trials), Kenya (three trials), Mozambique (two trials), Uganda (two trials), Cameroon (one
trial), Burkina Faso (one trial), and Thailand (two trials). Six different antimalarials were evaluated against placebo or no intervention;
chloroquine (given weekly), pyrimethamine (weekly or monthly), proguanil (daily), pyrimethamine-dapsone (weekly or fortnightly),
and mefloquine (weekly), or intermittent preventive therapy with SP (given twice, three times or monthly). Trials recruited women
in their first or second pregnancy (eight trials); only multigravid women (one trial); or all women (eight trials). Only six trials had
adequate allocation concealment.
For women in their first or second pregnancy, malaria chemoprevention reduces the risk of moderate to severe anaemia by around 40%
(RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants, high quality evidence), and the risk of any anaemia by around 17% (RR
0.83, 95% CI 0.74 to 0.93; five trials„ 3662 participants, high quality evidence). Malaria chemoprevention reduces the risk of antenatal
parasitaemia by around 61% (RR 0.39, 95% CI 0.26 to 0.58; seven trials, 3663 participants, high quality evidence), and two trials
reported a reduction in febrile illness (low quality evidence). There were only 16 maternal deaths and these trials were underpowered to
detect an effect on maternal mortality (very low quality evidence).
For infants of women in their first and second pregnancies, malaria chemoprevention probably increases mean birthweight by around
93 g (MD 92.72 g, 95% CI 62.05 to 123.39; nine trials, 3936 participants, moderate quality evidence), reduces low birthweight
by around 27% (RR 0.73, 95% CI 0.61 to 0.87; eight trials, 3619 participants, moderate quality evidence), and reduces placental
parasitaemia by around 46% (RR 0.54, 95%CI 0.43 to 0.69; seven trials, 2830 participants, high quality evidence). Fewer trials evaluated
spontaneous abortions, still births, perinatal deaths, or neonatal deaths, and these analyses were underpowered to detect clinically
important differences.
In multigravid women, chemoprevention has similar effects on antenatal parasitaemia (RR 0.38, 95% CI 0.28 to 0.50; three trials, 977
participants, high quality evidence)but there are too few trials to evaluate effects on other outcomes.
In trials giving chemoprevention to all pregnant women irrespective of parity, the average effects of chemoprevention measured in all
women indicated it may prevent severe anaemia (defined by authors, but at least < 8 g/L: RR 0.19, 95% CI 0.05 to 0.75; two trials,
1327 participants, low quality evidence), but consistent benefits have not been shown for other outcomes.
In an analysis confined only to intermittent preventive therapy with SP, the estimates of effect and the quality of the evidence were
similar.
A summary of a single trial in Thailand of prophylaxis against P. vivax showed chloroquine prevented vivax infection (RR 0.01, 95%
CI 0.00 to 0.20; one trial, 942 participants).
Authors’ conclusions
Routine chemoprevention to prevent malaria and its consequences has been extensively tested in RCTs, with clinically important
benefits on anaemia and parasitaemia in the mother, and on birthweight in infants.
P L A I N L A N G U A G E S U M M A R Y
The effect of taking antimalarial drugs routinely to prevent malaria in pregnancy
Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially
during the first or second pregnancy. For this reason, women are encouraged to try and prevent malaria infection during pregnancy by
sleeping under mosquito bed-nets, and by taking drugs effective against malaria throughout pregnancy as chemoprevention.
This Cochrane Review looked at all drug regimens compared to placebo. The review authors sought to summarise and quantify the
overall effects of chemoprevention. Seventeen trials were included, all conducted between 1957 and 2008, and all but two in countries
of Africa.
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For women in their first or second pregnancy, malaria chemoprevention prevents moderate to severe anaemia (high quality evidence);
and prevents malaria parasites being detected in the blood (high quality evidence). It may also prevent malaria illness. We don’t know if
it prevents maternal deaths, as this would require very large studies to detect an effect.
In their infants, malaria chemoprevention improves the average birthweight (moderate quality evidence), and reduces the number of
low birthweight infants (moderate quality evidence). We are not sure if chemoprevention reduces mortality of babies in the first week,
month and year, as again studies would need to be very large to show these effects.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Malaria chemoprevention for pregnant women (parity 0-1) living in endemic areas: maternal outcomes
Patient or population: Pregnant women (parity 0-1)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Mortality
All-cause death
7 per 1000 8 per 1000
(3 to 20)
RR 1.15
(0.44 to 3.06)
2097
(3 trials)
⊕©©©
very low1,2
Severe anaemia
During the third trimester
145 per 1000 87 per 1000
(68 to 108)
RR 0.60
(0.47 to 0.75)
2503
(3 trials)
⊕⊕⊕⊕
high3,4,5,6
Anaemia 649 per 1000 539 per 1000
(480 to 604)
RR 0.83
(0.74 to 0.93)
3662
(5 trials)
⊕⊕⊕⊕
high3,6,7,8
Uncomplicated clinical
malaria
173 per 1000 64 per 1000
(31 to 128)
RR 0.37
(0.18 to 0.74)
307
(2 trials)
⊕⊕©©
low4,9,10
Antenatal parasitaemia 286 per 1000 111 per 1000
(74 to 165)
RR 0.39
(0.26 to 0.58)
3663
(8 trials)
⊕⊕⊕⊕
high3,6,7,11
Severe adverse effects12 - - - - -
*The basis for the assumed risk (eg, the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: Only one of these trials adequately described allocation concealment to be considered at low risk of
selection bias.
2 Downgraded by 2 for imprecision: These trials were not adequately powered to detect a difference in mortality. Only 15 deaths occurred
in these three trials.To confidently detect a 25% reduction in maternal mortality in a setting of 350 deaths/100,000 would require a
sample size of over 100,000.
3 No serious risk of bias: Exclusion of the trials at high risk of bias did not change the statistical significance or clinical importance of the
result.
4 No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.
5 No serious indirectness: These trials were conducted in Kenya and Mozambique between 1996 and 2005, all three trials administered
IPT with SP. The definition of severe anaemia was variable; Hb <8 g/dL, Hb <7 g/dL, or PCV <21%.
6 No serious imprecision: This result is statistically significant and the meta-analysis is adequately powered to detect this effect.
7 No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in
the size of the effect.
8 No serious indirectness: These trials were conducted in Nigeria, Kenya and Uganda between 1978 and 1999. Three trials administered
IPT as SP, one gave weekly chloroquine, and one gave daily proguanil. The definition of anaemia was variable: Hb <12 g/dL, Hb <11 g/
dL, Hb <10 g/dL, PCV <33% and PCV <30%.
9 Downgraded by 1 for risk of bias. Both trials had high or unclear risk of selection bias and an attrition rate above 20%.
10 Downgraded by 1 for indirectness: Both these trials, from Cameroon 1993 and Mozambique 2002, measured fever history only as
proxy for malaria illness.
11 Not downgraded for inconsistency. Despite substantive quantitative heterogeneity (I2 69% across six trials), all show at least a
reduction of 23%, often more
11 No serious indirectness: These trials were conducted in The Gambia, Nigeria, Kenya and Mozambique between 1978 and 2005. Five
trials gave IPT as SP, one gave pyrimethamine-dapsone, one pyrimethamine, and one proguanil.
12 Reporting of adverse events was generally poor. No severe adverse events were reported.
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B A C K G R O U N D
Description of the condition
Approximately 125 million women living in malaria-endemic ar-
eas become pregnant each year (Dellicour 2010), and pregnancy
is known to increase the risk of malaria infection and the severity
of the illness compared to non-pregnant women in the same age
group (Desai 2007). Studies have also shown a strong association
between malaria infection in pregnancy and consequent maternal
anaemia, and low birthweight in infants, particularly in women
in their first or second pregnancy (Desai 2007; Steketee 2001).
To reduce the burden and consequences of malaria in pregnancy,
the World Health Organization (WHO) recommends that all
pregnant women living in malaria-endemic areas: i) sleep un-
der a long lasting insecticide-treated bednet (ITN; Gamble 2006;
WHO 2012); ii) are treated when anaemic or when ill with
malaria; and iii) receive some form of malaria chemoprevention.
Currently the WHO recommends ’intermittent-preventive ther-
apy’ with sulfadoxine-pyrimethamine (SP) during the second and
third trimesters in Africa (WHO 2013).
Description of the intervention
Over the years a variety of drugs have been evaluated for
malaria chemoprevention in pregnancy, including amodiaquine,
chloroquine, dapsone-pyrimethamine, mefloquine, proguanil,
pyrimethamine asmonotherapy and as the fixed dose combination
SP, and others. All have specific toxic and adverse effects, which
are outlined in standard texts (WHO 2010), and these may be
important factors influencing maternal adherence. For example,
proguanil can cause mouth ulcers, chloroquine can cause itch, and
mefloquine can cause dizziness and headaches.
How the intervention might work
Chemoprevention encompasses malaria chemoprophylaxis, and
also the use of treatment courses given regularly to women. This
is termed intermittent preventive treatment (IPT), defined as a
full therapeutic course of antimalarial medicine given to pregnant
women at routine prenatal visits, regardless of whether the recipi-
ent is infected with malaria. combines elements of a treatment ef-
fect through clearance or suppression of existing malaria infections
in the placental and peripheral blood of mother, and a post-treat-
ment prophylactic effect by preventing new infections for several
weeks after each dose (White 2005). Daily, weekly, or bi-weekly
malaria chemoprophylaxis is thought to work primarily through
the prevention of new malaria infections. However, a reduction
in malaria infections per se may be insufficient to justify the use
of chemoprevention for widespread use without subsequent bene-
fits on clinically important outcomes in the mother and her baby.
These may include a reduction in clinical malaria episodes, a re-
duced risk of anaemia, improved birthweight, or more substantive
outcomes such as a reduction in severe maternal illness, or fewer
deaths in the mother and infant (see Figure 1).
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Figure 1. Drugs for preventing malaria in pregnancy: conceptual framework.
The effects of malaria chemoprevention may differ between set-
tings dependent on the local malaria epidemiology. In highly en-
demic areas with stable transmission, mothers may have partial
immunity to malaria, and chronic subclinical placental infection
are common leading to maternal anaemia and low birthweight, es-
pecially in primi- and secundigravidae. In contrast, where malaria
transmission is low or unstable, the degree of life-long acquired
and pregnancy-specific protective immunity may be lower and
malaria infections are more likely to result in clinical episodes or
severe illness, leading to low birthweight due to a preterm birth,
foetal loss or maternal death.
Another potential effect modifier is HIV status. Many malaria-
endemic areas, especially in east and southern Africa, also have a
high prevalence of HIV infection among pregnant women. Com-
pared to HIV negative women, HIV positive women are more
likely to carry malaria parasites in their blood, have higher para-
site densities, and are more likely to have placental parasitaemia,
anaemia, and malaria symptoms and deliver low birthweight ba-
bies (Nkhoma 2012a; Nkhoma 2012b; ter Kuile 2004).
Why it is important to do this review
This Cochrane Review aims to address the following questions:
1. Does chemoprevention reduce mortality and substantive
outcomes in the mother and infant?
2. What is the potential reduction in the burden of malaria in
pregnancy that can be achieved by successful malaria
chemoprevention in pregnancy?
3. Are the effects consistent in low parity and high parity
women?
This review summarises the underpinning evidence of the pro-
tective efficacy achieved with antimalarial chemoprevention regi-
mens on the effects onmalaria and its consequences on themother
and baby when compared against placebo or no chemoprevention
(case-management strategies only). It does not compare different
regimens. These were included in earlier editions of this Cochrane
Review (Garner 2006); a more recent review has examined the
effects of different IPT regimens in pregnant women (Kayentao
2013).
O B J E C T I V E S
In malaria-endemic areas, to assess the effects in pregnant women
of:
1. Malaria chemoprevention versus no chemoprevention
irrespective of the regimen;
2. Malaria chemoprevention with SP (called intermittent
preventive treatment) with no chemoprevention;
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3. Preventive regimens for Plasmodium vivax.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs) and quasi-RCTs.
Types of participants
Pregnant women of any gravidity living in malaria-endemic ar-
eas, defined as regions where transmission occurs and malaria is a
characteristic of the region.
Types of interventions
Interventions
Any antimalarial drug chemoprevention regimen given to preg-
nant women.
Controls
Placebo or no intervention,
Types of outcome measures
For the conceptual framework, see Figure 1.
Maternal outcomes
• Impact: maternal deaths (number of maternal deaths
reported: death of a pregnant woman during pregnancy or
within 42 days of termination of pregnancy).
• Substantive outcomes: severe malaria, which includes severe
anaemia (defined as Hb < 8 g/dL, < 7 g/dL, < 6 g/dL); severe
adverse events.
• Clinically important outcomes: anaemia (anaemia defined
as Hb < between 10 and 12 g/dL); mean haemoglobin (g/dL) or
mean PCV (%); clinical malaria (history of fever episodes prior
to delivery); adverse events.
• Indicators of malaria infection: parasitaemia (defined as the
presence of asexual stage parasites in thick smears in peripheral,
placental, or cord blood).
Infant outcomes
• Impact: neonatal and Infant mortality.
• Substantive outcomes: foetal loss (including spontaneous
abortion (spontaneous expulsion of a fetus before it is able to
survive independently); stillbirth (birth of a foetus with no vital
signs, born after the 28th week of pregnancy); perinatal
mortality; severe adverse events, including congenital anomalies
(a defect that is present at birth).
• Clinically important outcomes: preterm birth (delivery at <
37 weeks gestation); low birthweight (< 2500 g); mean
birthweight; cord blood anaemia; adverse events.
• Indicators of malaria infection: placental malaria;
haemoglobin levels (infant), cord blood haemoglobin (g/dL),
and cord blood PCV; cord blood parasitaemia.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register (1 June 2014); Central Register of
Controlled Trials (CENTRAL); MEDLINE (1966 to 1 June
2014); EMBASE (1974 to February 2012); and LILACS (1982
to February 2012).
Researchers
We contacted researchers working in the field for unpublished
data, confidential reports, and raw data of published trials.
Reference lists
We also checked the citations of literature reviews, and of all trials
identified by the above methods, and asked the referees to check
the search strategy.
Data collection and analysis
Selection of studies
We applied inclusion criteria to all trials, including those in the
previous edition of this Cochrane Review. DR-P and PG indepen-
dently screened all trials identified by the search strategy (Appendix
1). Using a form based on the inclusion criteria, DR-P and PG
assessed eligibility independently. FK checked the completeness of
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the included trials. We retrieved full text articles for all potentially
relevant trials, applied the inclusion criteria, and then compared
decisions. We resolved any differences by discussion and, when
necessary, consulted with co-authors.Trials identified in the initial
abstract screening which did not meet the inclusion criteria are
listed in the ’Characteristics of excluded studies’.
Data extraction and management
DR-P andPG independently extracted data using a data extraction
form.We extracted data on trial characteristics, including trial site,
year, local malaria transmission and resistance, trial methods, par-
ticipants, interventions, doses and outcomes and entered this data
intoReviewManager 5.1. The number of participants randomized
and the number analysed in the experimental and control arms
were extracted in each group for each outcome. For dichotomous
outcomes, we recorded the number of participants experiencing
the event and the number assessed in each treatment group. For
continuous outcomes, we extracted the arithmetic means, stan-
dard deviations for each treatment group and the number of par-
ticipants assessed in each group. We calculated and reported the
loss to follow-up in each group.
Assessment of risk of bias in included studies
We independently assessed the trials’ methodological quality (risk
of bias) of each trial, using the Cochrane Collaboration’s tool for
assessing the risk of bias (Higgins 2011). The following six com-
ponents were assessed for each trial: generation of allocation se-
quence, allocation concealment, blinding (of participants, person-
nel, and outcome assessors), incomplete outcome data, selective
outcome reporting, and other sources of bias. Each component
was classified by ’yes’ (low risk of bias), ’no’ (high risk of bias), or
’unclear’ to indicate level of bias. Where our judgement was ’un-
clear’, we attempted to contact the trial authors for clarification.
Measures of treatment effect
We used the risk ratio (RR) to summarise dichotomous outcomes,
reported the mean difference for continuous outcomes, and used
the rate ratio for count outcomes. We presented all measures of ef-
fect with 95% confidence intervals (CI). One trial had four arms:
one a comparison of IPT with nets, and a second comparison with
no nets, and these were treated as separate comparisons (Njagi
2003i KEN; Njagi 2003ii KEN); a second trial had two interven-
tion comparisons, so in meta-analysis we split the control group
in half for dichotomous outcomes. For continuous outcomes, we
split the denominator of the control in half, but applied no cor-
rection to the standard deviation.
Unit of analysis issues
If the original trial analyses had not adjusted for clustering, we
planned to adjust the results for clustering bymultiplying the stan-
dard errors of the treatment effect by the square root of the de-
sign effect. The design effect would be calculated as 1+(m-1)*ICC
where m was the average cluster size and ICC was the intra-cluster
correlation coefficient.Weplanned to estimate the ICC fromother
trials included in the review or by contacting trial investigators.
We also planned to include trials with multiple treatment arms
if relevant to any of the comparisons. One trial randomized by
compound in The Gambia (Greenwood 1989 GMB). However,
we know that compounds are quite small, are grouped around
families, and that, even if two women were pregnant at the same
time in one family, this would not be quantitatively important in
terms of overestimating the precision of the effect estimate.
Dealing with missing data
We planned to use intention-to-treat (ITT) data from the original
trials, but it was more practical to use a complete-case analysis,
such that we excluded participants for whom no outcome was re-
ported from the analysis. This analysis assumes that the partici-
pants for whom an outcome is available are representative of the
original randomized patients. If data from the trial reports were
insufficient, unclear, or missing, we attempted to contact the trial
authors for additional information. In one trial with no standard
deviation for birthweight, we used the average of the standard de-
viation for the other included trials.
Assessment of heterogeneity
We inspected the forest plots to detect overlapping CIs, applying
the Chi2 test and a P value of 0.10 as the cut-off value to de-
termine statistical significance. We also estimated the I2-statistic
and categorized the degree of heterogeneity using standard cut-
offs (Higgins 2011).
Data synthesis
We used Review Manager 5.1 for the analysis.
Our primary analysis is stratified by parity, with results grouped
into women of low parity (0-1) and multigravidae (1+).
We included a category called ’all women’. This included trials that
recruited women irrespective of parity. This analysis included the
trials which had stratified the analysis by parity (and were therefore
included in the primary analysis), and a second set of trials, which
had not. This analysis provides information on the population
effects of a policy of providing chemoprevention to all pregnant
women.
We used RRs for dichotomous variables and mean differences
(MD) for continuous variables; all results are presented with 95%
CIs. In the absence of heterogeneity, we used a fixed-effect model
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for the meta-analysis, and where we detected heterogeneity we
used a random-effects model. Weighted averages were calculated
where required. We converted Packed Cell Volume (PCV) values
to haemoglobin values by dividing by three.
Subgroup analysis and investigation of heterogeneity
We grouped the analysis by parity. Although we intended to inves-
tigate heterogeneity by a variety of factors (including HIV status,
risk of bias, geographical region, malaria transmission pattern, an-
timalarial resistance, ITN use, drug regimen), there were insuffi-
cient data to do this.
R E S U L T S
Description of studies
Results of the search
The search was conducted up to 01 June 2014 for the time period
1964 to 2014, and identified 181 references of which two were
duplicate trial reports. Out of 179, we retrieved 53 full-text articles
for eligibility screening (Figure 2).
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Figure 2. Study flow diagram.
11Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Included studies
Seventeen chemoprevention trials, enrolling 20,256 pregnant
women, met our inclusion criteria (see ’Characteristics of included
studies’). These trials were conducted between 1957 and 2008,
in Nigeria (three trials), The Gambia (three trials), Kenya (three
trials), Mozambique (two trials), Uganda (two trials), Cameroon
(one trial), Burkina Faso (one trial), and Thailand (two trials).
Six different antimalarials were evaluated against placebo or no
preventive intervention (ie passive case detection and treatment of
clinical cases only); chloroquine (given weekly), pyrimethamine
(weekly or monthly), proguanil (daily), pyrimethamine-dapsone
(weekly or fortnightly), SP (given twice,monthly or intermittently
for up to four doses at least one month apart), and mefloquine
(weekly) (see Appendix 2). Fifteen trials reported that drug ad-
ministration was supervised, and in two trials it was unsupervised
(Fleming 1986 NGA; Ndyomugyenyi 2000 UGA).
Eight trials recruited women in all parity groups; four reported
aggregate results, and four disaggregated by parity. The rest only
recruited lowparitywomen: sixwere parity 0, and twowerewomen
of parity 0-1. One trial only recruitedmultigravidae (see Appendix
3).
In four trials, all women in both intervention and control groups
received a long-lasting ITNs at recruitment (Menendez 2008
MOZ; Ndyomugyenyi 2000 UGA; Ndyomugyenyi 2011 UGA;
Njagi 2003i KEN). One additional trial mentioned that ITNs
were in use in the area, with a use of 26% (Shulman 1999 KEN;
ter Kuile 2007). In six trials iron and folic acid were routinely
administered to all pregnant women (Fleming 1986 NGA;Mbaye
2006 GMB; Nahlen 1989 NGA; Njagi 2003i KEN; Njagi 2003ii
KEN;Parise 1998i KEN;Parise 1998ii KEN;Villegas 2007THA),
in one trial only iron was administered (Shulman 1999 KEN), and
in one trial both iron and folic acid were given to anaemic women
(Nosten 1994 THA). The remaining trials did not comment on
use of iron or folic acid.
One trial was randomized by compound, but for the analysis we
assumed that it was individually randomized (Greenwood 1989
GMB). Two trials with multiple intervention arms were presented
by individual arms, and the placebo patients split between the
two arms where the treatment arms were both included in the
meta-analysis; Parise 1998i KEN compared two doses of SP versus
no intervention while Parise 1998ii KEN compared monthly SP
versus no intervention; Njagi 2003i KEN compared SP + ITNs
versus placebo + ITNs; and Njagi 2003ii KEN compared SP alone
versus placebo.
Excluded studies
We excluded 32 trials for the reasons given in the ’Characteristics
of excluded studies’ table. Also in this review update, we excluded
one previously included trial (Hamilton 1972 UGA) as iron was
administered to one of the control groups and folic acid to the
other, but nothing was mentioned of iron and folates being ad-
ministered to women in the intervention group (chloroquine).
Risk of bias in included studies
See Figure 3 for a summary of the risk of bias assessments. We
have presented further details in the ’Characteristics of included
studies’ tables.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Allocation
Six trials adequately describedmethods of sequence generation and
allocation concealment to be considered at low risk of selectionbias
(Fleming 1986 NGA;Mbaye 2006 GMB;Menendez 2008MOZ;
Ndyomugyenyi 2011 UGA; Shulman 1999 KEN; Villegas 2007
THA). Four trials were quasi-RCT and so at high risk of selection
bias (Cot 1992 BFA; Cot 1995 CMR; Morley 1964 NGA; Parise
1998i KEN; Parise 1998ii KEN), and in the remaining seven trials
the risk was unclear.
Blinding
Eleven trials used placebo tablets, identical in taste and appear-
ance to the active drug, and were assessed as having low risk of
performance bias.
Four trials explicitly stated that outcome assessors were blinded
and were assessed as having low risk of detection bias (Cot 1992
BFA; Morley 1964 NGA; Ndyomugyenyi 2011 UGA; Villegas
2007 THA). In the remaining included trials the risk was unclear.
Incomplete outcome data
Six trials had an attrition rate lower than 10% in both the inter-
vention and control arm (Menendez 2008 MOZ; Morley 1964
NGA; Nahlen 1989 NGA; Ndyomugyenyi 2011 UGA; Nosten
1994 THA; Villegas 2007 THA). The remaining 11 trials were at
high or unclear risk of attrition bias.
Selective reporting
Birthweight data were not available in one trial, but we obtained
this data from a subsequent review (Njagi 2003i KEN; Njagi
2003ii KEN; ter Kuile 2007).
Other potential sources of bias
In one trial, 18 participants were replaced by others after random-
ization (Fleming 1986 NGA). We sought differences in baseline
values with haemoglobin (Analysis 1.4) and detected no obvious
difference.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1; Summary of findings 2 Summary of findings
table 2; Summary of findings 3 Summary of findings table 3;
Summary of findings 4 Summary of findings table 4; Summary
of findings 5 Summary of findings table 5; Summary of findings
6 Summary of findings table 6; Summary of findings 7 Summary
of findings table 7; Summary of findings 8 Summary of findings
table 8
Comparison 1: Chemoprevention (any drug regimen)
versus placebo/no chemoprevention
Chemoprevention for women in their first or second
pregnancy
Maternal outcomes (see Summary of findings for the main
comparison)
Only 15 maternal deaths were reported across all trials with no
difference between groups (three trials, 2097 participants, Analysis
1.1, very low quality evidence). Maternal death, even in these set-
tings, is a relatively rare event occurring in less than five women per
1000 pregnancies. Consequently trials would need to enrol over
125,000 women to be adequately powered to detect or exclude
effects as large as a 25% relative reduction (see Table 1).
No trials reported on episodes of severe malaria, but three trials
reported moderate to severe anaemia (defined as Hb < 7/8 g/dL
or PCV < 21%). Overall, chemoprevention was associated with
a 40% reduction in the risk of moderate to severe anaemia in
the third trimester (RR 0.60, 95% CI 0.47 to 0.75; three trials,
2503 participants, Analysis 1.2, high quality evidence). This effect
was consistent despite variation in doses, and differences in the
definition and timing of assessment for severe anaemia (I2 =0);
Parise 1998ii KEN recorded severe anaemia at delivery (after three
doses of SP); Shulman 1999 KEN at 34 weeks (after three doses of
SP);Menendez 2008MOZ at delivery (after two doses of SP), and
Parise 1998i KEN at the beginning of the third trimester clinic
visit (when the second dose of SP was due, and these women had
only had one SP dose).
Chemoprevention was also associated with a reduction in the risk
of any anaemia (defined as Hb < 10/11/12 g/dL or PCV < 33%/
30%), although this reduction was generally of smaller magnitude
(RR 0.83, 95% CI 0.74 to 0.93; five trials, 3662 participants,
Analysis 1.3, high quality evidence). In addition, measures of mean
haemoglobin in the third trimester were higher in those receiving
chemoprevention (MD0.41 g/dL, 95%CI 0.29 to 0.54; five trials,
3363 participants, Analysis 1.4).
Chemoprevention was associated with fewer episodes of presumed
clinical malaria (history of fever), but this outcome was only re-
ported in two small trials (RR 0.37, 95% CI 0.18 to 0.74; two
trials, 307 participants, Analysis 1.5, low quality evidence). Instead
most trials reported antenatal parasitaemia, defined as either par-
asitaemia at delivery or parasitaemia at 34 to 36 weeks, with most
trials showing benefits but wide variation in the size of the reduc-
tion (RR 0.39, 95% CI 0.26 to 0.58; eight trials, 3663 partici-
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pants, I2 = 82; Analysis 1.6, high quality evidence) This heterogene-
ity is probably not unexpected given the differences in chemopre-
vention regimens and malaria endemicity.
Infant outcomes (see Summary of findings 2).
The trials and the meta-analyses are underpowered to confidently
detect or exclude effects on spontaneous abortion, perinatal deaths,
or neonatal deaths (see Table 1). The CIs range from important
benefits to no evidence of any harm in four outcomes: sponta-
neous abortions (RR 0.65, 95% CI 0.41 to 1.02; five trials, 2876
participants, Analysis 1.9, low quality evidence); perinatal deaths
(RR 0.73, 95% CI 0.54 to 1.00; two trials, 1620 participants,
Analysis 1.11, low quality evidence); neonatal deaths (RR 0.62,
95% CI 0.37 to 1.05; two trials, 2156 participants, Analysis 1.12,
low quality evidence). The preterm births analysis was (RR 0.85,
95% CI 0.66 to 1.10; two trials, 1493 participants, Analysis 1.13,
low quality evidence).
Chemoprevention was associated with fewer low birthweight in-
fants (RR 0.73, 95% CI 0.61 to 0.87; eight trials, 3619 partici-
pants, Analysis 1.14, moderate quality evidence). and mean birth-
weight was higher with chemoprevention (MD 92.72 g, 95% CI
62.05 to 123.39; nine trials, 3936 participants, Analysis 1.15,
moderate quality evidence).
One very small trial reportednodifference in the prevalence of cord
blood anaemia (64 participants, Analysis 1.16), and a lower cord
blood haemoglobin in babies born to women receiving chemo-
prevention (MD -1.80 g/dL, 95% CI -3.46 to -0.14; one trial, 64
participants, Analysis 1.17, very low quality evidence).
Chemoprevention resulted in fewer cases of placental parasitaemia
(RR 0.54, 95% CI 0.43 to 0.69; seven trials, 2830 participants,
Analysis 1.17, high quality evidence). Only one trial examined cord
blood parasitaemia, but there were too few events to be confident
of the result (RR 0.47, 95% CI 0.22 to 1.01; one trial, 1335 par-
ticipants, Analysis 1.19). The children born to mothers receiving
monthly SP had reduced cord parasitaemia, whereas those born
to mothers receiving two doses of SP did not (Parise 1998i KEN).
Chemoprevention for multigravidae
Maternal outcomes (see Summary of findings 3).
Four trials provided data on multigravidae women. Only one trial
assessed mortality with six deaths in the chemoprevention group
and four in the control group (RR 1.47, 95% CI 0.42 to 5.21; one
trial, 2239 participants, Analysis 1.1, very low quality evidence).
No trials reported episodes of severe malaria, but two reported
severe anaemia. In one trial more women had severe anaemia in
the chemoprevention group (RR 1.20, 95% CI 0.91 to 1.57; one
trial, 1954 participants), and the second trial had few events and
consequently very wide CIs (RR 0.41, 95% CI 0.08 to 2.09; one
trial, 728 participants). The 95% CIs of the overall meta-analysis
does not exclude effects as large as those seen in women in their
first or second pregnancy but this is probably unlikely (RR 0.96,
95% CI 0.41 to 2.25; two trials, 2682 participants, Analysis 1.2).
No trials reported the risk of mild anaemia, but two trials reported
mean haemoglobin at delivery without clinically important dif-
ferences between groups (MD 0.01 g/dL, 95% CI -0.23 to 0.24;
two trials, 676 participants, Analysis 1.4).
No trial measured malaria or febrile episodes in the mother. Four
trials reported antenatal parasitaemia, and all four trials report
large effects of a similar magnitude to those seen in women in their
first or second pregnancy (RR 0.38, 95% CI 0.28 to 0.50; four
trials, 3022 participants, Analysis 1.6, high quality evidence).
Infant outcomes (see Summary of findings 4).
Two trials included information on infant outcomes after chemo-
prevention given to multigravid women.
Spontaneous abortions, stillbirths and perinatal deaths were not
reported.One trial reported deaths in the first six weeks of life with
slightly higher deaths following chemoprevention, but with wide
CIs including the possibility of no difference between groups (RR
1.46, 95% CI 0.90 to 2.38; one trial, 2017 participants, Analysis
1.12).
No trials reportedmean birthweight in infants born tomultigravid
women, but three reported the risk of low birthweight. The trend
is in favour of chemoprevention but neither the trials, or themeta-
analysis reached standard levels of statistical significance (RR 0.86,
95%CI 0.64 to 1.17; three trials, 2743 participants, Analysis 1.14,
very low quality evidence).
No trials reported measures of placental parasitaemia, cord blood
parasitaemia, or cord blood haemoglobin.
Chemoprevention for all women
To evaluate the population effects of a policy of chemoprevention
for all pregnant women, regardless of parity, this third analysis
includes all trials which recruited women of any parity. Some of
these presented results stratified by parity and were included in
the analyses above, but a few additional trials did not provide their
outcome data stratified by parity.
Maternal outcomes (see Summary of findings 5).
Formaternalmortality, only ninematernal deaths were recorded in
trials recruiting women of all parities; 4/3019 with chemopreven-
tion and 5/3007 without (four trials, 6026 participants, Analysis
1.1, low quality evidence).
For severe anaemia in the mother, there were very few events
recorded in the two trials but the risk was lower with chemopre-
vention (RR 0.19, 95% CI 0.05 to 0.75; two trials, 1327 partici-
pants, Analysis 1.2, low quality evidence). For any anaemia, no pop-
ulation differences were demonstrated (RR 1.03, 95% CI 0.87 to
1.23; three trials, 3027 participants, Analysis 1.3, moderate quality
evidence). Three trials reported mean haemoglobin, with only one
very small trial from the early 1990s finding benefit with chemo-
prevention (three trials, 2223 participants, Analysis 1.4).
Clinical malaria (or history of fever) was reported in four of the
trials across all parity groups. The older, and smaller trials, sug-
gested a population benefit on clinical malaria but this was not
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seen in the two recent and much larger trials using two doses of SP
(four trials, 3455 participants, Analysis 1.5, low quality evidence).
For parasitaemia at delivery, there was considerable heterogeneity
between trials (I2 = 79%).Of the twomost recent trials, both large,
and both administering two doses of SP, one trial from Mozam-
bique demonstrated a benefit with chemoprevention and one from
Uganda did not (five trials, 3961 participants, Analysis 1.6, low
quality evidence).
Infant outcomes (see Summary of findings 6).
In trials recruiting women of all parities, no differences were
demonstrated for spontaneous abortions (three trials, 5767 par-
ticipants, Analysis 1.9, low quality evidence), stillbirths (five trials,
7130 participants, Analysis 1.10, moderate quality evidence), peri-
natal deaths (four trials, 5216 participants, Analysis 1.11, mod-
erate quality evidence), or neonatal and infant deaths (five trials,
6313 participants, Analysis 1.12, moderate quality evidence). We
also pooled across all trials for these outcomes (including those
which only recruited women in their first or second pregnancies),
and no differences were demonstrated.
Population benefits for the infants were not demonstrated for pre-
term birth (two trials, 1174 participants, Analysis 1.13, low quality
evidence), low birthweight (four trials, 3644 participants, Analysis
1.14, low quality evidence), or mean birthweight (five trials, 6007
participants, Analysis 1.15, moderate quality evidence).
The effects of chemoprevention on placental parasitaemia were
mixed (I2 = 94%), with large effects in two older trials admin-
istering monthly pyrimethamine or weekly chloroquine, and no
effect demonstrated in the two more recent trials administering
two doses of SP (four trials, 3200 participants, Analysis 1.18, low
quality evidence).
One trial in Mozambique found a large effect in reducing the risk
of cord blood anaemia (RR 0.49, 95% CI 0.30 to 0.80; one trial,
870 participants, Analysis 1.16), and increase in mean cord PCV
(MD 1.01%, 95% CI 0.05 to 1.97; one trial, 990 participants,
Analysis 1.17).
Adverse effects
We aggregated adverse effects across all parity groups. Reporting of
adverse effects was generally poor.Only five trials specifically stated
that no adverse effects attributable to the drugs were observed in
the mothers, and the rest either did not report adverse effects or
the information was unclear. Four trials reported adverse events
following SP (Analysis 1.7), and one trial following mefloquine
(Analysis 1.8). No differences were seen between the treatment
and control groups.
Again, reporting of adverse events in the neonate was generally
poor. Episodes of neonatal kernicterus were reported in two trials,
and congenital anomalies in two trials, with nodifferences detected
(Analysis 1.20).
Comparison 2. SP IPT chemoprevention for women in their
first or second pregnancy
The above analysis examines the effects of drugs known to be
effective in preventing malaria at the particular time the trials
were carried out. As theWHOcurrently recommends intermittent
dosing with SP, we performed an additional analysis to provide
the effect estimates for SP compared to no drug or placebo. The
analysis is exactly the same as comparison one, but we included
only the six SP trials. These trials administered SP in two doses
(Parise 1998i KEN;Njagi 2003i KEN;Njagi 2003ii KEN; Challis
2004MOZ;Menendez 2008MOZ;Ndyomugyenyi 2011UGA),
three doses (Shulman 1999 KEN), or monthly (Parise 1998ii
KEN).
Maternal outcomes (see Summary of findings 7).
For maternal death, no effect was demonstrated but the analysis
is underpowered (Analysis 2.1).
For women of low parity, restricting the analysis to trials of SP did
not substantially change the estimates of benefit on severe anaemia
(RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants,
Analysis 2.2, high quality evidence), mild anaemia (RR 0.88, 95%
CI 0.88 to 0.96; three trials, 3219 participants, Analysis 2.3, mod-
erate quality evidence), or mean haemoglobin (MD 0.41 g higher,
95%CI 0.27 to 0.54; three trials, 2995 participants, Analysis 2.4).
Similarly, the reduction in antenatal parasitaemia is consistent with
the overall effect from trials of any chemoprevention (RR 0.38,
95% 0.24 to 0.59; four trials, 2832 participants, Analysis 2.5, high
quality evidence), but there is insufficient data to draw conclusions
on clinical malaria (RR 0.24, 95% CI 0.05 to 1.12; one trial, 174
participants, very low quality evidence (Analysis 2.6).
Infant outcomes (see Summary of findings 8).
The trials and the meta-analyses are underpowered to confidently
detect or exclude effects on spontaneous abortion, stillbirth, peri-
natal deaths, or neonatal deaths, but restricting the analysis to tri-
als of SP did not substantially change the estimates of effect (see
Analysis 2.7; Analysis 2.8; Analysis 2.9; Analysis 2.10; low quality
evidence). The trend is towards a reduction in pre-term birth but
the 95% CI is wide and includes the possibility of no effect (RR
0.85, 95% CI 0.66 to 1.10; two trials, 1493 participants, Analysis
2.11, low quality evidence).
Overall, chemoprevention with SP reduced the incidence of low
birthweight but this effect seems to be reducing over time, with
large effects in the older trials and no effect seen in the more recent
trials using two doses of SP (four trials, 3043 participants, Analysis
2.12, moderate quality evidence). However, mean birthweight was
higher with SP, and this effect was still present in the most recent
trials (MD 105.5 g, 95% CI 68.02 to 142.9, four trials, 2693
participants, Analysis 2.13, moderate quality evidence).
Chemoprevention with SP reduced placental parasitaemia (RR
0.45, 95%CI 0.33 to 0.61; three trials, 1633 participants, Analysis
2.14, high quality evidence) but only one trial of SP reported cord
parasitaemia (RR 0.47, 95% CI 0.22 to 1.01; one trial, 1335
participants, Analysis 2.15).
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Cochrane Collaboration.
Adverse effects
No effects were detected with icterus (two trials, 2233 partici-
pants, Analysis 2.16) or congenital abnormalities (one trial, 1017
participants, Analysis 2.16).
Comparison 3. Chemoprevention for P. vivax
Only one trial reported on chemoprevention for P. vivax, con-
ducted in Thailand with weekly prophylaxis with chloroquine. It
was rated at low risk of bias on all criteria. It seemed to prevent
completely all episodes of P. vivax malaria (RR 0.01, 95% CI 0.00
to 0.20; 942 participants, see Table 2), but had no effect on ma-
ternal anaemia, low birthweight, or mean birthweight. It was un-
derpowered to assess effects on mortality.
17Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Malaria chemoprevention for pregnant women (parity 0-1) living in endemic areas: infant outcomes
Patient or population: Pregnant women (parity 0-1)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Spontaneous abortion 33 per 1000 21 per 1000
(13 to 33)
RR 0.65
(0.41 to 1.02)
2876
(5 trials)
⊕⊕©©
low1,2,3,4
Stillbirth 33 per 1000 32 per 1000
(21 to 49)
RR 0.97
(0.64 to 1.49)
2703
(3 trials)
⊕⊕©©
low2,4,5,6,
Perinatal mortality 104 per 1000 76 per 1000
(56 to 104)
RR 0.73
(0.54 to 1.00)
1620
(2 trials)
⊕⊕©©
low2,4,5,7,
Neonatal mortality 37 per 1000 23 per 1000
(14 to 39)
RR 0.62
(0.37 to 1.05)
2156
(2 trials)
⊕⊕©©
low2,4,5,7,
Preterm birth 164 per 1000 140 per 1000
(108 to 181)
RR 0.85
(0.66 to 1.10)
1493
(2 trials)
⊕⊕©©
low1,2,4
Low birthweight 152 per 1000 110 per 1000
(92.7 to 132.2)
RR 0.73
(0.61 to 0.87)
3619
(8 trials)
⊕⊕⊕©
moderate9,10
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Mean birthweight The mean birthweight in the
control groups ranged from
2723 g to 3079 g
The mean birthweight in the
intervention groups was
92.72 g higher
(62.05 higher to 123.39
higher)
- 3936
(9 trials)
⊕⊕⊕©
moderate5,10
Placental parasitaemia 307 per 1000 160 per 1000
(132 to 211)
RR 0.54
(0.43 to 0.69)
2830
(7 trials)
⊕⊕⊕⊕
high3,11,12
Cord blood haemoglobin The mean haemoglobin in the
control group was
15.8 g/dL
The mean haemoglobin in the
intervention groups was
1.8 g/dL lower
(3.46 lower to 0.14 lower)
- 64
(1 trial)
⊕©©©
very low1,13,14
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: None of the trials described adequate measures to prevent selection bias.
2 No serious inconsistency: The effect is consistent across trials and statistical heterogeneity is low.
3 No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya and Mozambique between 1990 and 2002.
One gave chemoprevention as weekly chloroquine and four trials gave IPT with SP.
4 Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.
5 Downgraded by 1 for serious risk of bias: Only one trial adequately described methods to prevent selection bias.
6 No serious indirectness: Trials were conducted in Cameroon and Kenya between 1993 and 1997. One trial gave weekly chloroquine
and the others gave IPT as SP.
7 No serious indirectness: The trials were conducted in The Gambia and Kenya between 1984 and 1997. One trial used IPT with SP and
one gave pyrimethamine-dapsone which is no longer in use.
8 No serious indirectness: Both trials were conducted in Kenya and used IPT with SP.
9 Downgraded by 1 for serious risk of bias: Only two of these trials were at low risk of selection bias.
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10 No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya, Uganda and Mozambique between 1986 and
2005. The majority of trials used IPT with SP.
11 No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in
the size of the effect.
12 No serious indirectness: These trials were conducted in The Gambia, Cameroon, Kenya, Uganda and Mozambique between 1990 and
2002. The majority of trials used IPT with SP.
13 Downgraded by 1 for serious indirectness: This single trial used a regimen that is no longer in use (proguanil).
14 Downgraded by 1 for serious imprecision: Only a single small trial has evaluated this comparison.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Malaria chemoprevention for pregnant women (parity 2+) living in endemic areas: maternal outcomes
Patient or population: Pregnant women (parity 2+)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Mortality
All-cause death
5 per 1000 7 per 1000
(2 to 26
RR 1.47
(0.42 to 5.21)
2239
(1 trial)
⊕©©©
very low1,2,3
Severe anaemia
During the third trimester
68 per 1000 65 per 1000
(28 to 153)
RR 0.96
(0.41 to 2.25)
2682
(2 trials)
⊕⊕©©
low1,4,5
Anaemia The mean PCV in the control
group was
30.4 %
The mean PCV in the interven-
tion group was
0.3 % higher
(0.7 lower to 1.3 higher)
- 244
(1 trial)
⊕©©©
very low6,7,8
Uncomplicated clinical
malaria
- - - -
(0 trials)
-
Antenatal parasitaemia 108 per 1000 41 per 1000
(30 to 54)
RR 0.38
(0.28 to 0.50)
3022
(4 trials)
⊕⊕⊕⊕
high9,10
Severe adverse events11 - - - - -
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
2
1
D
ru
g
s
fo
r
p
re
v
e
n
tin
g
m
a
la
ria
in
p
re
g
n
a
n
t
w
o
m
e
n
in
e
n
d
e
m
ic
a
re
a
s:
a
n
y
d
ru
g
re
g
im
e
n
v
e
rsu
s
p
la
c
e
b
o
o
r
n
o
tre
a
tm
e
n
t
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
A
u
th
o
rs.
T
h
e
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: These trials are at low risk of bias.
2 Downgraded by 1 for serious indirectness: This single trial was conducted in The Gambia between 2002 and 2004 and administered
IPT as monthly SP. The findings may not be easily generalised to elsewhere.
3 Downgraded by 2 for very serious imprecision: Only ten deaths occurred in this trial. Much larger trials would be needed to detect or
exclude effects on maternal mortality.
4 No serious indirectness: These two trials were conducted in The Gambia in 2002-2004 and Mozambique between 2003 and 2005.
5 Downgraded by 2 for very serious imprecision: The 95% CI are very wide and include the possibility of both clinically important benefits
and harms.
6 Downgraded by 1 for serious risk of bias: This single trial is at unclear risk of selection bias.
7 Downgraded by 1 for serious indirectness: This trial administered chemoprevention as pyrimethamine-dapsone which is no longer in
use.
8 Downgraded by 1 for serious imprecision: A much larger sample size is required to confidently detect or exclude an effect.
9 No serious risk of bias: Two of the four trials were at low risk of selection bias and exclusion of the other two trials did not change the
size of the effect.
10 No serious indirectness: These three trials were conducted in The Gambia, Nigeria and Mozambique between 1986 and 2005. The
biggest and most recent trial administered IPT with SP (two doses)
11 Reporting of adverse events was generally poor. No severe adverse events were reported.
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Malaria chemoprevention for pregnant women (parity 2+) living in endemic areas: infant outcomes
Patient or population: Pregnant women (parity 2+)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Spontaneous abortion - - - -
(0 trials)
-
Stillbirth - - - -
(0 trials)
-
Perinatal deaths - - - -
(0 trials)
-
Neonatal mortality 26 per 1000 38 per 1000
(23 to 62)
RR 1.46
(0.90 to 2.38)
2017
(1 trial)
⊕©©©
very low1,2,3
Preterm birth - - - -
(0 trials)
-
Low birthweight 60 per 1000 63 per 1000
(46 to 85)
RR 0.86
(0.63 to 1.17)
2743
(3 trials)
⊕⊕©©
low 3,4,5
Mean birthweight - - - -
(0 trials)
-
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Placental parasitaemia - - - -
(0 trials)
-
Cord blood haemoglobin - - - -
(0 trials)
-
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: This single trial was at low risk of selection bias.
2 Downgraded by 1 for serious indirectness: This single trial was conducted in The Gambia between 2002 and 2004 and administered
IPT as monthly SP. The findings may not be easily generalised to elsewhere.
3 Downgraded by 2 for serious imprecision: The 95% CI is very wide and includes clinically important effects and no effect. A much
larger sample size is required to confidently detect or exclude an effect.
4 No serious risk of bias: These trials are at low risk of selection bias.
5 No serious indirectness: These trials were conducted in The Gambia, Mozambique, and Uganda between 2002 and 2008.
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Malaria chemoprevention for all pregnant women (all parities) living in endemic areas: maternal outcomes
Patient or population: Pregnant women (all parities)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Mortality
All-cause death
1 per 1000 1 per 1000
(0 to 3)
RR 0.84
(0.25 to 2.74)
6026
(4 trials)
⊕⊕©©
low1,2,3
Severe anaemia
During the third trimester
26 per 1000 5 per 1000
(1 to 19)
RR 0.19
(0.05 to 0.75)
1327
(2 trials)
⊕⊕©©
low2,4,5,6
Anaemia 206 per 1000 212 per 1000
(179 to 253)
RR 1.03
(0.87 to 1.23)
3027
(3 trials)
⊕⊕⊕©
moderate1,2,7,8
Uncomplicated clinical
malaria
114 per 1000 42 per 1000
(13 to 140)
RR 0.37
(0.11 to 1.23)
3455
(4 trials)
⊕⊕©©
low1,9,10
Antenatal parasitaemia 152 per 1000 106 per 1000
(67 to 172)
RR 0.70
(0.44 to 1.13)
3455
(4 trials)
⊕⊕©©
low1,8,11
Severe adverse effects12 - - - -
(0 trials)
-
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: The two most recent trials adequately described allocation concealment to be considered at low risk of selection
bias.
2 No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.
3 Downgraded by 2 for very serious imprecision: These trials were not adequately powered to detect a difference in mortality. Only nine
deaths occurred in these four trials. To confidently detect a 25% reduction in maternal mortality in a setting of 350 deaths/100,000 would
require a sample size of over 100,000.
4 No serious risk of bias: One of these two trials adequately described allocation concealment to be at low risk of bias.
5 Downgraded by 1 for serious indirectness: Only a single trial from Mozambique provides data on the currently used regimen of IPT as
two doses of SP. The definition of severe anaemia was PCV <21%.
6 Downgraded by 1 for serious imprecision: The number of events is very low and the trials underpowered to be confident in these
results.
7 No serious indirectness: These trials were conducted in Thailand, Mozambique and Uganda between 1988 and 2008. The two recent
trials administered IPT as two doses of SP. The definition of anaemia was variable; Hb <11 g/dL, PCV <33% and PCV <30%.
8 Downgraded by 1 for serious imprecision: Although the finding is of no effect. The 95% CI includes what may be clinically important
differences.
9 Downgraded by 1 for serious inconsistency: The two old trials from 1957 and 1988 suggest clinically important benefits with
chemoprophylaxis - however, the two recent trials providing two doses of SP find no evidence of an effect.
10 Downgraded by 1 for serious indirectness: The finding of no effect in the two recent trials may be due to the declining efficacy of two
doses of SP.
11 Downgraded for by 1 for serious inconsistency. There is substantive heterogeneity between trials (I2 = 79%), and this finding of no
effect is in contrast to findings of benefit in both women of low parity and multigravidae. The finding of no effect in two of the recent trials
may reflect declining efficacy in the regimens used.
12 Reporting of adverse events was generally poor. No severe adverse events were reported.
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Malaria chemoprevention for pregnant women (all parities) living in endemic areas: infant outcomes
Patient or population: Pregnant women (all parities)
Settings: Malaria-endemic areas
Intervention: Malaria chemoprevention (any regimen)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Chemoprevention
Spontaneous abortion 12 per 1000 11 per 1000
(7 to 16)
RR 0.89
(0.58 to 1.36)
5767
(3 trials)
⊕⊕©©
low1,2,3,4
Stillbirth 22 per 1000 22 per 1000
(17 to 30)
RR 1.02
(0.76 to 1.36)
7130
(5 trials)
⊕⊕⊕©
moderate1,2,5
Perinatal mortality 33 per 1000 41 per 1000
(31 to 54)
RR 1.24
(0.94 to 1.63)
5216
(4 trials)
⊕⊕⊕©
moderate1,2,5
Neonatal mortality 62 per 1000 56 per 1000
(44 to 72)
RR 0.91
(0.71 to 1.16)
6313
(5 trials)
⊕⊕⊕©
moderate1,2,5
Preterm birth 85 per 1000 81 per 1000
(55 to 117)
RR 0.95
(0.65 to 1.38)
1174
(2 trials)
⊕⊕©©
low2,5,6,10
Low birthweight 119 per 1000 126 per 1000
(106 to 151)
RR 1.06
(0.89 to 1.27)
3644
(4 trials)
⊕⊕©©
low1,2,5,10
Mean birthweight The mean birthweight in the
control groups ranged from
2797 g to 3161 g
The mean birthweight in the
intervention groups was
0.54 g lower
(24.6 g lower to 23.6 g higher)
- 6007
(5 trials)
⊕⊕⊕©
moderate1,7,8,10
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Placental parasitaemia 181 per 1000 80 per 1000
(27 to 233)
RR 0.44
(0.15 to 1.29)
3200
(4 trials)
⊕⊕©©
low1,9,10
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No serious risk of bias: The two most recent trials adequately described allocation concealment to be considered at low risk of selection
bias.
2 No serious inconsistency: The finding of no difference is consistent across trials and statistical heterogeneity is low
3 No serious indirectness: These trials were conducted in the Burkina Faso, Mozambique and Uganda between 1988 and 2008. One
gave chemoprevention as weekly chloroquine and two trials gave IPT with SP.
4 Downgraded by 2 for very serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.
5 Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.
6 No serious risk of bias: The most recent trial adequately described allocation concealment to be considered at low risk of selection bias.
7 No serious inconsistency: Although substantial statistical heterogeneity is present (I2 = 72%), this relates to the oldest trial which
found a benefit with chemoprevention. The subsequent four trials have consistently found no clinically important difference.
8 No serious imprecision: The 95% CI probably excludes clinically important benefits.
9 Downgraded by 1 for serious inconsistency: The two old trials from 1957 and 1988 suggest clinically important benefits with
chemoprophylaxis - however, the two recent trials providing two doses of SP find no evidence of an effect.
10 Downgraded by 1 for serious indirectness: The finding of no effect in the recent trials may be due to the declining efficacy of two
doses of SP which is no longer recommended.
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Intermittent preventive treatment with SP for pregnant women (parity 0-1) living in malaria endemic areas: maternal outcomes
Patient or population: Pregnant women (parity 0-1)
Settings: Malaria-endemic areas
Intervention: Intermittent preventive treatment with SP (2 doses, 3 doses, or monthly dosing)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control IPT (SP)
Mortality
All-cause death
7 per 1000 8 per 1000
(3 to 20)
RR 1.15
(0.44 to 3.06)
2097
(2 trials)
⊕©©©
very low1,2
Severe anaemia
During the third trimester
145 per 1000 87 per 1000
(68 to 108)
RR 0.60
(0.47 to 0.75)
2503
(3 trials)
⊕⊕⊕⊕
high3,4,5,6
Anaemia 617 per 1000 543 per 1000
(480 to 604)
RR 0.88
(0.81 to 0.96)
3291
(4 trials)
⊕⊕⊕©
moderate1,6,7,8
Uncomplicated clinical
malaria
9 per 100 2 per 100
(0 to 10)
RR 0.24
(0.05 to 1.12)
174
(1 trial)
⊕©©©
very low9,10,11
Antenatal parasitaemia 286 per 1000 108 per 1000
(69 to 169)
RR 0.38
(0.24 to 0.59)
2832
(4 trials)
⊕⊕⊕⊕
high3,6,7,12
Severe adverse effects13 - - - -
(0 trials)
-
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for risk of bias: Only one of these trials adequately described allocation concealment to be considered at low risk of
selection bias.
2 Downgraded by 2 for imprecision: These trials were not adequately powered to detect a difference in mortality. Only 15 deaths occurred
in these two trials. To confidently detect a 50% reduction in maternal mortality in a setting of 350 deaths/100,000 would require a sample
size of over 100,000.
3 No serious risk of bias: Exclusion of the trials at high risk of bias did not change the statistical significance or clinical importance of the
result.
4 No serious inconsistency: This finding was consistent across all trials and statistical heterogeneity was low.
5 No serious indirectness: These trials were conducted in Kenya and Mozambique between 1996 and 2005, all three trials administered
IPT with SP. The definition of severe anaemia was variable; Hb <8 g/dL, Hb <7g/dL, or PCV <21%.
6 No serious imprecision: This result is statistically significant and the meta-analysis is adequately powered to detect this effect.
7 No serious inconsistency: Although statistical heterogeneity was high, all trials favoured IPT with SP but there was variability in the size
of the effect.
8 No serious indirectness: These trials were conducted Kenya between 1996 and 1999. The definition of anaemia was variable; Hb <11
g/dL, Hb <10 g/dL.
9 Downgraded by 1 for risk of bias: This trial is at unclear risk of selection bias.
10 Downgraded by 1 for indirectness: This trial from Mozambique 2002, measured fever history only as proxy for malaria illness.
11 Downgraded by 1 for serious imprecision: The 95% CI is wide and includes clinically important benefits and no effect.
12 No serious indirectness: These trials were conducted in the Kenya and Mozambique between 1996 and 2005.
13Reporting of adverse events was generally poor. No severe adverse events were reported.
3
0
D
ru
g
s
fo
r
p
re
v
e
n
tin
g
m
a
la
ria
in
p
re
g
n
a
n
t
w
o
m
e
n
in
e
n
d
e
m
ic
a
re
a
s:
a
n
y
d
ru
g
re
g
im
e
n
v
e
rsu
s
p
la
c
e
b
o
o
r
n
o
tre
a
tm
e
n
t
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
4
T
h
e
A
u
th
o
rs.
T
h
e
C
o
c
h
ra
n
e
D
a
ta
b
a
se
o
f
S
y
ste
m
a
tic
R
e
v
ie
w
s
p
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
o
n
b
e
h
a
lf
o
f
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
Intermittent preventive treatment with SP for pregnant women (parity 0-1) living in malaria endemic areas: infant outcomes
Patient or population: Pregnant women (parity 0-1)
Settings: Malaria-endemic areas
Intervention: Intermittent preventive treatment with SP (2 doses, 3 doses, or monthly dosing)
Control: Placebo or no intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control IPT (SP)
Spontaneous abortion 34 per 1000 21 per 1000
(13 to 33)
RR 0.61
(0.38 to 0.99)
2567
(3 trials)
⊕⊕©©
low1,2,3,4
Stillbirth 33 per 1000 32 per 1000
(21 to 49)
RR 0.97
(0.64 to 1.47)
2703
(3 trials)
⊕⊕©©
low2,4,5,6
Perinatal mortality 80 per 1000 62 per 1000
(42 to 94)
RR 0.78
(0.52 to 1.17)
1237
(1 trial)
⊕⊕©©
low7
Neonatal mortality 37 per 1000 23 per 1000
(14 to 39)
RR 0.62
(0.37 to 1.05)
2156
(2 trials)
⊕⊕©©
low2,4,5,6
Preterm birth 164 per 1000 140 per 1000
(108 to 181)
RR 0.85
(0.66 to 1.10)
1493
(2 trials)
⊕⊕©©
low1,2,4
Low birthweight 128 per 1000 104 per 1000
(86 to 127)
RR 0.81
(0.67 to 0.99)
3043
(4 trials)
⊕⊕⊕©
moderate8,9
Mean birthweight The mean birthweight in the
control groups ranged from
2908 g to 3079 g
The mean birthweight in the
intervention groups was
84.18 g higher
(40.1 to 128.3 higher)
- 2127
(3 trials)
⊕⊕⊕©
moderate5,9
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Placental parasitaemia 225 per 1000 101 per 1000
(74 to 137)
RR 0.45
(0.33 to 0.61)
1633
(3 trials)
⊕⊕⊕©
moderate5,10
Cord blood haemoglobin - - - -
(0 trials)
-
*The basis for the assumed risk (eg the median control group risk across trials) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the
comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded by 1 for serious risk of bias: None of the trials described adequate measures to prevent selection bias.
2 No serious inconsistency: The effect is consistent across trials and statistical heterogeneity is low
3 No serious indirectness: These trials were conducted in the Kenya and Mozambique between 1996 and 2002.
4 Downgraded by 1 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.
5 Downgraded by 1 for serious risk of bias: Only one trial adequately described methods to prevent selection bias.
6 No serious indirectness: Trials were conducted in Kenya between 1996 and 1997.
7 Downgraded by 2 for serious imprecision: The 95% CI is wide and sample remains underpowered to detect or rule out an effect.
8 Downgraded by 1 for serious risk of bias: Only two of these trials were at low risk of selection bias.
9 No serious indirectness: These trials were conducted in the Kenya, Uganda and Mozambique between 1996 and 2008.
10 No serious inconsistency: Although statistical heterogeneity was high, all trials favoured chemoprevention but there was variability in
the size of the effect.
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D I S C U S S I O N
Summary of main results
We included 17 trials, enrolling 14,481 pregnant women, in this
Cochrane Review.
For women in their first or second pregnancy, malaria chemopre-
vention reduces the risk of moderate to severe anaemia by around
40% (high quality evidence), and the risk of any anaemia by around
17% (high quality evidence).Malaria chemoprevention reduces the
risk of antenatal parasitaemia by around 61% (high quality evi-
dence), and two trials reported a reduction in febrile illness (low
quality evidence). There were only 16 maternal deaths and these
trials were underpowered to detect an effect on maternal mortality
(very low quality evidence).
For infants of women in their first and second pregnancies,
malaria chemoprevention probably increases mean birthweight by
around 93 g (moderate quality evidence), reduces low birthweight
by around 27% (moderate quality evidence), and reduces placental
parasitaemia by around 46% (high quality evidence). Fewer trials
evaluated spontaneous abortions, still births, perinatal deaths, or
neonatal deaths, and these analyses were underpowered to detect
clinically important differences.
In multigravid women, chemoprevention has similar effects on
antenatal parasitaemia (high quality evidence) but there are too few
trials to evaluate effects on other outcomes.
In trials giving chemoprevention to all pregnant women irrespec-
tive of parity, the average effects of chemoprevention measured in
all women indicated it may prevent severe anaemia (low quality
evidence), but consistent benefits have not been shown for other
outcomes.
In an analysis confined only to intermittent preventive therapy
with SP, the estimates of effect and the quality of the evidence were
similar.
A summary of a single trial inThailand of prophylaxis against vivax
showed chloroquine prevented vivax infection (RR 0.01, 95% CI
0.00 to 0.20; 942 participants).
Overall completeness and applicability of
evidence
Trials were almost exclusively from Africa and published between
1964 and 2011. These trials, from a variety of settings and using
varied chemoprevention regimens, found fairly consistent clini-
cally important benefits for low parity women and their infants.
However, it is possible that with the introduction of ACTs, de-
clining malaria transmission in some areas of Africa, and increas-
ing quality of antenatal services, that the attributable fraction of
malaria towards maternal anaemia and low birthweight has been
reduced and the large effects seen in these trials may be attenuated
by less malaria and better individualized care of women during
pregnancy.
Quality of the evidence
The evidence for effects onmaternal, foetal and neonatal mortality
is generally considered of low or very low quality because the
trials and the meta-analysis remain significantly underpowered to
confidently prove or exclude clinically important effects.
For women of low parity, we considered the evidence of clinically
important effects on anaemia and antenatal parasitaemia to be of
high quality, meaning we can have confidence in these results. For
the infants of women of low parity, we considered the effects on
birthweight to only be of moderate quality because of the high risk
of bias of most of the older trials. This means we can have only
moderate confidence in the magnitude of these effects.
Trials did not describe the routine health services available to de-
tect and treat malaria infection in both intervention and control
arms, but many trials were done some years ago in areas with very
basic curative health services available. However, in the future with
declining levels of malaria the individual management of illness
and malaria at clinic may become an important option to control
malaria in pregnancy.
Potential biases in the review process
It seems unlikely that we have missed any trials. As trials did not
systematically document adverse effects, it is likely that these have
been underestimated in this review.
Agreements and disagreements with other
studies or reviews
The findings of this Cochrane Review are consistent with previ-
ous editions (Garner 2006; ter Kuile 2007). The findings are also
consistent with the findings of a review comparing observational
and randomized evidence (McClure 2013). McClure 2013 points
out that the fairly modest effects seen in RCTs, where delivery of
care is often strengthened and adherence assured, were attenuated
in the observational studies where, the authors surmise, delivery of
the intervention and adherence to it may be attenuated. However,
this contrasts with a study estimating the effects of IPT with SP on
low birthweight and neonatal mortality from survey data: the trial
estimates are remarkably similar to the results observed with IPT
with SP from the trial data reported in this and previous analysis
(Eisele 2012; ter Kuile 2007).
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Implications for practice
Routine chemoprevention to preventmalaria and its consequences
has been extensively tested in RCTs, with clinically important ben-
efits on anaemia and parasitaemia in the mother, and on birth-
weight in infants.
The data also assists in showing the potential attribution ofmalaria
towards key endpoints, and what can be achieved by successful
prevention to assist in modelling studies examining the impact of
malaria on pregnancy.
Implications for research
Identifying current effective chemoprevention regimens remains
a challenge, especially with the spread of drug-resistant malaria,
in particular against SP which is the only antimalarial currently
recommended for IPT in pregnant women. There is justification
for assessing the safety and efficacy of effects of alternative drugs
that can replace SP in areas with high SP resistance, or alternative
strategies that could replace IPT during pregnancy, such as inter-
mittent screen and treat (IST) approaches that focus on prompt
accessible treatment for anaemia and asymptomatic parasitaemia
(Tagbor 2010).
All new trials should systematically and carefully collect adverse
effects of regimens.
The data on the longer term impact on infants is poor and needs
further study: currently the evidence mainly relates to effects on
clinically important outcomes, such as preterm birth and birth-
weight.
There is a dearth of data from endemic areas outside of Africa,
such as Asia and Latin America.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Challis 2004 MOZ
Methods Trial design: RCT
Data collected: 2001 to 2002
Length of follow-up: from first antenatal visit to first week after delivery
Frequency of follow-up: monthly
Participants Parity: 0-1
Number: 600
Inclusion criteria: nulliparous and primiparous women under 21 years
Excluded: none stated
Interventions 1. SP (3 tablets): at enrolment and in third trimester
2. Placebo
Other: clinical malaria symptoms treated with CQ, SP or quinine and tetracycline irre-
spective of allotment
Administration supervised: yes
Outcomes 1. Parasitaemia at second visit
2. Placenta malaria
3. Birthweight
Notes Location: Mozambique
Urban/rural: both (women from Matola - town and Boane - village)
Malaria transmission: 20% prevalence
Drug resistance: chloroquine resistance present
HIV prevalence: 10%
Funding: Department of Research Co-operation with Developing countries (SAREC) at
the Swedish InternationalDevelopmentAuthority (Sida) and fromMidSwedenResearch
and Development Centre (FoU)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The data were analysed on an ITT basis.
ITT includes a random allocation proce-
dure producing comparable groups and an
analysis of the data according to the way we
intended to treat the subjects”
Women were “randomly assigned” to re-
ceive SP or placebo. No sufficient informa-
tion provided how the allocation sequence
was generated
Allocation concealment (selection bias) Unclear risk Packages of SP or placebo tablets.
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Challis 2004 MOZ (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Three tablets (SP or placebo) were given
in a double-blind manner: either SP/SP -
an initial treatment dose of SP at enrolment
with a second dose at the beginning of the
third trimester; or placebo/placebo…The
placebo dose was three similar tablets in
shape and colour as SP tablets.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided, except that all slides
were analysed and double checked at
the malaria laboratory at the Ministry of
Health
Incomplete outcome data (attrition bias)
All outcomes
High risk At second dose: 189/600 = 31.5% lost to
follow-up.
At delivery: 309/600 women = 51.5% lost
to the follow-up peripheral blood analyses
(153/300 = 51% from the placebo group
and 156/300 = 52% from the SP group)
Selective reporting (reporting bias) Low risk No selective reporting observed.
Other bias Low risk None identified.
Cot 1992 BFA
Methods Trial design: Quasi-RCT
Data collected: 1987 to 1988
Length of follow-up: approximately five months (from the first visit to the clinic which
was for most women before the 5th month of pregnancy, until delivery)
Frequency of follow-up: twice a week
Participants Parity: all women
Number: 1464
Inclusion criteria: every pregnant woman attending urban maternal and child health
centre
Excluded: none stated
Interventions 1. Chloroquine: weekly
2. Nothing
Other: no information
Administration supervised: yes
Outcomes 1. Placental parasitaemia
2. Mean birthweight and low birthweight
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Cot 1992 BFA (Continued)
Notes Location: Burkina Faso
Urban/rural: urban (the city of Banfora)
Malaria transmission: hyperendemic, with seasonal transmission
Drug resistance: chloroquine resistance may be present
19% parasitaemia in trial population
Funding: INSERM (Institut National de Ia Santé et de Ia Recherche Médicale): Reseau
Nord-Sud no. 486 NS2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “For the sake of simplicity, an alternate al-
location of treatment was performed, in
which the women were divided into two
groups (treated and control).”
No specific procedure used to generate al-
location sequence.
Allocation concealment (selection bias) High risk Allocation not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk “For technical reasons, it was not possible
to give a placebo to women in the control
group.”
Participants and personnel were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Laboratory technicians had no informa-
tion on the status of the individuals from
whom the samples had been taken, as did
the midwives who weighed the newborn
babies”
Outcome assessors were blinded.
Incomplete outcome data (attrition bias)
All outcomes
High risk High attrition rate: 263/1464 (17.96%)
. There were 20.3 % (151/745 women)
with no outcome in the experimental
arm (chloroquine): 29 excluded after ran-
domization (stillbirths, abortions, multiple
pregnancies). The other 122/745 women
(16.4%) delivered outside of the hospital.
There were 22.9% (165/719 women) with
no outcome in the control arm: 24 ex-
cluded, 141/719 (19.6%) delivered outside
of the hospital
Selective reporting (reporting bias) Low risk No selective reporting observed.
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Cot 1992 BFA (Continued)
Other bias Unclear risk Approximately 20womenwere allocated to
the control group at the beginning of the
trial and reclassified in the treated group
a few days later. “These subjects were not
clearly identified, and it was impossible to
exclude them afterwards.”
Cot 1995 CMR
Methods Trial design: Quasi-RCT
Data collected: 1991 to 1993
Length of follow-up: from first prenatal visit until delivery (two to five months)
Frequency of follow-up: weekly
Participants Parity: para 0
Number: 266
Inclusion criteria: primigravidae antenatal clinic attendees
Excluded: none stated
Interventions 1. Chloroquine: 300 mg per week until delivery
2. Nothing
Other: no information
Administration supervised: yes
Outcomes 1. Antenatal parasitaemia
2. Placental malaria
3. Birthweight
Notes Location: Cameroon
Urban/rural: urban (town of Ebolowa)
Malaria transmission: hyperendemic area with high transmission all year round
Drug resistance: moderate chloroquine resistance
Funding: Ministère Français de la Coopération (FAC paludisme)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “After being examined by the hospital
physician, any primigravida living in the
study area and attending the clinic for a
first prenatal visit… was introduced to an
investigator who obtained their informed
consent and allocated them alternately to
a chloroquine treatment (CQ) group or a
control (CT) group.”
Trial described as “randomized, double-
blind”, but participants were “alternately
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Cot 1995 CMR (Continued)
allocated”
Allocation concealment (selection bias) High risk Allocation not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk “Women in the control group followed the
usual hospital procedures; placebos were
not used”
Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors were
blinded. No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate was 21.4% (28/131) in the
experimental arm (chloroquine) and 21.
5% (29/135) in the control arm for the du-
ration of the pregnancy
Selective reporting (reporting bias) Low risk No selective reporting observed. Antenatal
parasitaemia not clearly reported
Other bias High risk “Of the CT group women, 39 (56%) de-
clared that on their own initiative, they had
taken one or more short treatments of ei-
ther chloroquine or amodiaquine during
the course of their pregnancy because they
thought they had contracted malaria.” Pos-
sible protocol violation
Fleming 1986 NGA
Methods Trial design: RCT
Data collected: unclear (before 1985). First attendance to the clinic: 1977 to 1978
Length of follow-up: from first prenatal visit until 6 weeks after delivery
Frequency of follow-up: at least once every two weeks up to the 36th week of gestation
and subsequently, weekly until delivery
Haematological observations were performed at first attendance, 28 weeks and 36 weeks
of gestation, at delivery and 6 weeks postpartum
Participants Parity: para 0
Number: 200
Inclusion criteria: primigravidae under 16 years attending antenatal clinic; Hausa tribe
Excluded: severe anaemia
Interventions 1. Proguanil daily
2. Placebo
Other: all received single dose chloroquine on entry; folic acid and iron supplements
included in randomized design
Administration supervised: no
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Fleming 1986 NGA (Continued)
Outcomes 1. Antenatal parasitaemia and haemoglobin
2. Birthweight
Notes Location: Nigeria
Urban/rural: urban (Zaria)
Malaria transmission: unstable area with seasonal transmission
Drug resistance: none
Funding: WHO, Ahmadu Bello University, Smith Kline and French Laboratories Ltd
(UK) and Imperial Chemical Industries
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants “randomly allocated” to one of
five treatment groups, using random num-
bers table
Allocation concealment (selection bias) Low risk “Neither the researchers nor the patients
were aware of the treatment allocated until
after the completion of the study.”
Treatment allocation code was used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The manufacturers supplied active tablets
or spansules and the placebos, which could
not be distinguished by sight.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear whether outcome assessors were
blinded. No information provided
Incomplete outcome data (attrition bias)
All outcomes
High risk “Only 89 women out of 200 delivered in
the hospital... 12/200 (6%) did not attend
again (the clinic) after the first or second
visits; a further 72/200 (36%) did not con-
tinue until the postnatal visit.”
Inadequate details but there is evidence to
suggest that the attrition rate was quite high
Selective reporting (reporting bias) Low risk No selective reporting observed.
Other bias Unclear risk “18 patients were replaced in the trial by
others; this was arranged by a moderator
(Dr. B. M. Greenwood), who was not oth-
erwise involved in the research, but had ac-
cess to the treatment allocation code for this
purpose…Eighteen patients were replaced
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Fleming 1986 NGA (Continued)
in the trial by others.”
Greenwood 1989 GMB
Methods Trial design: Trial randomized by compound
Data collected: 1984 to 1987
Length of follow-up: from first prenatal visit until one week after delivery
Frequency of follow-up: unclear but administration was on weekly basis
Participants Parity: all women
Number: 1049
Inclusion criteria: all women in trial villages who became pregnant; some sub-studies
only followed up primigravidae
Excluded: none stated
Interventions 1. Pyrimethamine 25 mg and dapsone 100 mg: fortnightly
2. Placebo
Given by village people employed by the project
Other: no information
Administration supervised: yes
Outcomes 1. Antenatal parasitaemia
2. Birthweight
3. Packed cell volume
4. Maternal death
5. Perinatal death
6. Infant death
Notes Location: The Gambia
Urban/rural: urban
Malaria transmission: seasonal
Drug resistance: none reported
Funding: Unclear
For the analysis we assumed that it is individually RCT
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Once a woman had reported to a tradi-
tional birth attendant that she was preg-
nant, she was allocated to receive one tablet
of Maloprim fortnightly or placebo and is-
sued with a record card by an MRC field
worker. Randomization was by compound.
”
No details provided of a specific procedure
used to generate allocation sequence
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Greenwood 1989 GMB (Continued)
Allocation concealment (selection bias) Unclear risk “Treatment was indicated on the record
card by a pictorial representation of a
coloured tablet (white for Maloprim, pink
for placebo)”
Insufficient details provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo tablets used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “1208 pregnancies which progressed be-
yond the 28th week were recorded dur-
ing the 3 years of the survey. During 1049
(87%) of these pregnancies women re-
ported to the TBA resident and received
one or more doses of Maloprim or placebo.
”
Unclear risk. Assumption is that attrition
rate was 13.2% (159/1208, where 159 =
1208-1049)
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Low risk None identified.
Mbaye 2006 GMB
Methods Trial design: RCT
Data collected: 2002 to 2004
Length of follow-up: From the 1st antenatal visit to 1 year after delivery
Frequency of follow-up: twice per week before delivery; 6 weeks and 1 year after delivery
Participants Parity: multigravidae only
Number: 2688
Inclusion criteria: pregnancy of more than 15 weeks duration
Excluded: Hb concentration of < 7 g/dL; allergy to sulphonamides; severe or chronic
disease
Interventions 1. 3 tablets of SP (up to 4 drug administrations; mean gap 29 days)
2. 3 tablets of placebo (up to 4 administrations; mean gap 28 days)
Other: iron and folic acid for all
Administration supervised: yes
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Mbaye 2006 GMB (Continued)
Outcomes 1. Maternal mortality
2. Prevalence of peripheral parasitaemia after delivery
3. Anaemia/Hb
4. Birth outcomes
5. Infant death (death by 6 weeks)
Notes Location: The Gambia
Urban/rural: urban (around the town Farafenni)
Malaria transmission: seasonal
Drug resistance: unknown
HIV:HIVnegativewomen; prevalence ofHIV infection among antenatal clinic attenders
< 1%
Funding: The Medical Research Council and the Gates Malaria Partnership, funded by
the Bill and Melinda Gates foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Women were individually randomized in
blocks of 12”.
Allocation concealment (selection bias) Low risk “Tablets were pre-packed in en-
velopes…pre-labelledwith the same packet
number and placed in a wallet bearing the
subject’s number and packet number.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Identical SP and placebo tablets used.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate quite high: 459/2688 (17.1
%): Loss to follow-up in SP group 223/
1346 (16.6%) and in the placebo group
236/1342 (17.6%)
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Unclear risk Limited information obtained on bednet
use (an important variable in determining
the efficacy of IPT). Actual birthweights
obtained from only 5% of women (87% of
the newborn babies were weighed between
3 and 5 days after birth)
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Menendez 1994 GMB
Methods Trial design: Cluster-RCT
Data collected: 1987 to 1990
Length of follow-up: from first antenatal visit to third day after delivery
Frequency of follow-up: unclear but administration by traditional birth attendants was
on weekly basis
Participants Parity: 0
Number: 230
Inclusion criteria: primigravidae resident in trial area
Excluded: none stated
Interventions 1. Pyrimethamine and dapsone: weekly (one tablet of Maloprim weekly:
pyrimethamine 12.5 mg and dapsone 100 mg)
2. Placebo
Given by village people employed by the project
Other: no information
Administration supervised: yes
Outcomes 1. Placental malaria
2. Pregnancy outcomes
3. Birthweight
4. Neonatal mortality
Notes Location: The Gambia
Urban/rural: rural (trial area: 15 villages and 3 hamlets, 12 to 35 km from the town of
Farafenni)
Malaria transmission: seasonal
HIV: no information provided
Drug resistance: none reported
Funding: no information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “a randomized, double-blind,
placebo-controlled community based trial”
but no details of the way allocation se-
quence was generated are provided
Allocation concealment (selection bias) Unclear risk “After consent had been obtained, women
were randomized by compound of resi-
dence to receive weekly either one tablet of
Maloprim or placebo.”
Comment: insufficient detail.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded.
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Menendez 1994 GMB (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Unclear.
“Two hundred and thirty women were re-
cruited into the study over a 3-year pe-
riod…”
Afterwards, only 82 women are mentioned
as participants in the maloprim group and
89 women in the placebo group. Overall
attrition rate 59/230 (25.7%)
The total number of women with incom-
plete outcome data 28/230 (12.2%). Four
women had an abortion, 17 had stillbirths,
five women died, and 2 other women (0.
9%) were lost to follow-up
Selective reporting (reporting bias) Low risk No selective reporting observed.
Other bias Low risk No other source of bias identified.
Menendez 2008 MOZ
Methods Trial design: RCT
Data collected: August 2003 to April 2005
Length of follow-up: from recruitment until 8 weeks postpartum
Frequency of follow-up: unclear. Mean number of outpatient visits during pregnancy 1.
64 in the SP and 1.83 in the placebo group. Mean number of visits post-partum 0.69
in the SP group and 0.68 in the placebo group
Participants Parity: all
Number: 1030
Inclusion criteria: permanent residents of the CISM trial area with gestational age ≤ 28
weeks
Excluded: allergic to sulpha drugs
Interventions 1. Two doses of SP given at least one month apart
2. Placebo - same
Other: ITNs
Administration supervised: yes
Outcomes 1. Maternal mortality
2. Peripheral parasitaemia
3. Any placental malaria infection (fever episode)
4. Severe anaemia (PCV < 21%)
5. Pregnancy outcomes
6. Perinatal mortality
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Menendez 2008 MOZ (Continued)
7. Neonatal mortality
8. Birthweight
9. Pre-term birth
10. Cord blood parasitaemia
11. Cord blood anaemia (PCV < 37%)
12. Newborn gestational age
Notes Location: Mozambique
Urban/rural: urban
Malaria transmission: perennial malaria transmission with some seasonality
Drug resistance: evidence suggests that SP was highly effective in the area during the trial
HIV: In the SP group, 26.5% (117/441 women), and in the placebo group, 21.2% (91/
429 women). Overall: 23.9%
Funding: Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III (grant
numberCM03/00125); BancodeBilbao,Vizcaya, Argentaria Foundation (grant number
BBVA 02-0); Spanish Agency for International Cooperation (AECI)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated sequential list con-
tained the study numbers linked to treat-
ment identification letters, randomly or-
dered in blocks of 10”
Allocation concealment (selection bias) Low risk “Tablets of SP or placebo... were stored in
10 bottles labelled only with a single treat-
ment identification letter.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk SP and placebo tablets “identical in shape
and colour”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the SP group 35/515 (6.8%) did not re-
ceive 2 doses and birthweight was not mea-
sured for 7/501 (1.4%) live births. In the
placebo group 29/515 (5.6%) did not re-
ceive 2 doses and birthweight was not mea-
sured for 7/503 (1.4%) live births
Selective reporting (reporting bias) Low risk None identified (trial protocol available).
Other bias Unclear risk Data were analysed by ITT analysis
whereby all randomized women were in-
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Menendez 2008 MOZ (Continued)
cluded regardless of whether or not they
had received the intervention and the num-
ber of doses. Women with a multiple deliv-
ery (twins or triplets) as well as those who
did not receive all three doses were also in-
cluded in the analysis
Morley 1964 NGA
Methods Trial design: Quasi-RCT
Data collected: 1957
Length of follow-up: from first antenatal visit to delivery
Frequency of follow-up: insufficient detail (drugs given monthly)
Participants All women
Number: 429
Inclusion criteria: all pregnant women registered at dispensary
Excluded: none stated
Interventions 1. Pyrimethamine: monthly
2. Placebo
Other: fever treated with chloroquine sulphate in both groups
Administration supervised: women were given drugs during antenatal visits
Outcomes 1. Antenatal weight gain
2. Fever episodes
3. Parasitaemia
4. Placental infection
5. Birthweight
6. Perinatal mortality
Notes Location: Nigeria
Urban/rural: rural (the village of Imesi)
Malaria transmission: holoendemic area
Drug resistance: none
Funding: no information
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “As the pregnant women were registered at
the dispensary, they were given consecutive
numbers and allotted to one or other of two
groups. All womenwith evennumberswere
given 2 tablets (50 mg) of pyrimethamine
once a month… The control group (the
odd numbers) were given two tablets of
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Morley 1964 NGA (Continued)
placebo”
Comment: not randomized.
Allocation concealment (selection bias) Unclear risk Insufficient detail provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Pyrimethamine and “similar tablets”
placebo were used
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Blood films were examined in the hospital
laboratory…The technicians did not know
to which group a mother belonged.”
Assessors blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Birthweight: data available for 93.7%(402/
429 women). Incomplete data outcome for
6.3% (27/429) women: 17 stillbirths and
10 twin deliveries were excluded
Selective reporting (reporting bias) Low risk No selective reporting observed.
Other bias Low risk None identified.
Nahlen 1989 NGA
Methods Trial design: RCT
Data collected: from January to June 1988
Length of follow-up: 77 days (mean interval from day 7 post-chloroquine treatment to
documentation of parasitaemia was 74 days for pyrimethamine group)
Frequency of follow-up:weekly. Follow-up examinations andblood smearswere obtained
on days 2, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, and 77
Participants Parity: all
Number: 71
Inclusion criteria: antenatal and attending hospital and health centre; < 34 weeks gesta-
tion; no recent chloroquine taken; parasitaemic > 500 parasites/µL blood
Excluded: history of antimalarial drug ingestion during the previous week
Interventions 1. Pyrimethamine (25 mg): weekly
2. Nothing
Other: treated with two doses of chloroquine at recruitment; folic acid and iron given
to all women
Administration supervised: yes
Outcomes 1. Antenatal parasitaemia
Notes Location: Nigeria
Urban/rural: urban (Ilorin, the capital of Kwara State)
Malaria transmission: endemic area
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Nahlen 1989 NGA (Continued)
Drug resistance: possible pyrimethamine resistance present
Funding: US Agency for International Development, Africa Child Survival-Initiative-
Combatting Childhood Communicable Diseases Project, 698-0421
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Women in group 2 were assigned ran-
domly to a pyrimethamine treatment or a
control group.”
The statement that women were randomly
assigned is insufficient to be confident that
the allocation sequence was genuinely ran-
domized
Allocation concealment (selection bias) High risk “The treated group was observed to take 25
mg of pyrimethamine weekly and was in-
structed to take folic acid and iron supple-
ments daily, while the control group took
only folic acid and iron daily.”
Allocation not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “In vivo tests were completed successfully
in all 71 women enrolled.”
Comment: Therewere nomissing outcome
data.
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Low risk None identified.
Ndyomugyenyi 2000 UGA
Methods Trial design: RCT
Data collected: 1996 to 1998
Length of follow-up: from first antenatal visit to first week postpartum
Frequency of follow-up: monthly
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Ndyomugyenyi 2000 UGA (Continued)
Participants Parity: 0
Number: 860
Inclusion criteria: primigravidae
Excluded: severe anaemia (< 8 g)
Interventions 1. Chloroquine
2. Placebo
3. Iron + folate (not included in the analysis)
Other: clinical malaria symptoms treated with 25 mg/kg of chloroquine for three days,
ITNs
Administration supervised: no
Outcomes 1. Haemoglobin
2. Birthweight
Notes Location: Uganda
Urban/rural: rural (Hoima District)
Malaria transmission: hyperendemic area
Drug resistance: unknown
Funding: The Danish Bilharziasis Laboratory, Denmark
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “After clinical and laboratory examination,
women were randomly assigned to 1 of the
3 intervention group”
Insufficient details.
Allocation concealment (selection bias) Unclear risk No information provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo and active tablets of the same
colour and shape.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided to make a judge-
ment whether or not the outcome assessors
were blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk A high attrition rate of 32.6% (268 out of
823 women were lost to follow-up)
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Low risk None identified.
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Ndyomugyenyi 2011 UGA
Methods Trial design: individually RCT
Data collected: 2004 to 2008
Length of follow-up: from first antenatal visit to 28 days after delivery
Frequency of follow-up: regularly through ANC clinics, and every seven days postnatally
Participants Parity: all parities
Number: 5775 randomized; 4715 singleton births followed up
Inclusion criteria: pregnant women < 27 weeks at first clinic visit
Excluded: > 26 weeks pregnant, non-residents and temporary residents
Interventions 1. ITNs + placebo
2. ITNS + IPT
3. IPT
Drugs given under direct observation. Two doses of SP.
Outcomes Prevalence of maternal anaemia (Hb < 11.0 g/L)
mean Hb at 36 to 40 weeks
Clinical malaria
Peripheral and placental parasitaemia
Abortions, preterm births, stillbirths, perinatal deaths, neonatal deaths
Low birthweight
Mean birthweight
Notes Location: Kabale Highlands, Uganda
Urban/rural: rural
Malaria transmission: low/unstable area
Drug resistance: SP thought to be effective
HIV: low
Funding: Gates Partnership
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated random number
list”.
Allocation concealment (selection bias) Low risk “individual sealed envelopes”.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Tablets of SP or placebo, identical in shape
and colour”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All study participants, health staff and re-
searchers were blind to drug assignment
(SP or placebo)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Delivery follow-up: 92%, 92%, and 93%
to one month.
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Ndyomugyenyi 2011 UGA (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk None identified.
Njagi 2003i KEN
Methods RCT
Participants Low parity (0-1)
Number: 963
Inclusion criteria: gestational age of between 12 and 24 weeks
Exclusion criteria: HIV/AIDS, severe systemic diseases
Interventions 1. ITN + IPT-SP (2 doses)
2. ITN + placebo (2 doses)
Other: Folic acid and iron given to all women
Administration supervised: yes
Outcomes 1. Maternal anaemia
2. Maternal mortality
3. Birth outcomes: abortions
Length of follow-up: From 1st antenatal visit to 1 week after delivery
Frequency of follow-up: monthly antenatal clinic visits
Notes Location: Western Kenya
Malaria transmission: intense
Drug resistance: unknown
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random number sequences in blocks of 12.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo and active drug tablets were of equal size, colour and
shape. The investigators had no knowledge of the assigned
groups until after data collection, editing and data analysis were
completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
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Njagi 2003i KEN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate 17.4% (168/963): 114 lost due to migration, 35
- home delivery, 19 - refused to continue. Attrition rate in ITN
and SP group 35/242 (14.5%), in ITN and placebo group 32/
238 (13.4%), in SP group 52/245 (21.2%), in placebo group
49/238 (20.6%). Together with the exclusions, 211/963 (21.
9%) women with no treatment outcome
Selective reporting (reporting bias) Unclear risk Mentioned that mode of delivery, birthweight and baby’s Hb
were recorded but they were never reported. The trial report fails
to include results for a key outcome that would be expected to
have been reported for such a trial
Other bias Low risk None identified.
Njagi 2003ii KEN
Methods As for Njagi 2003i KEN
Participants As for Njagi 2003i KEN
Interventions 1. IPT-SP (2 doses)
2. Placebo (2 doses)
Other: Folic acid and iron given to all women
Outcomes As for Njagi 2003i KEN
Notes As for Njagi 2003i KEN
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random number sequences in blocks
of 12.
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo and active drug tabletswere of equal size, colour and
shape. The investigators had no knowledge of the assigned
groups until after data collection, editing and data analysis
were completed.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
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Njagi 2003ii KEN (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition rate 17.4% (168/963): 114 lost due to migration,
35 - home delivery, 19 - refused to continue. Attrition rate
in ITN and SP group 35/242 (14.5%), in ITN and placebo
group 32/238 (13.4%), in SP group 52/245 (21.2%), in
placebo group 49/238 (20.6%). Together with the exclu-
sions, 211/963 (21.9%) women with no treatment outcome
Selective reporting (reporting bias) Unclear risk Mentioned that mode of delivery, birthweight and baby’s
Hb were recorded but they were never reported. The trial
report fails to include results for a key outcome that would
be expected to have been reported for such a trial
Other bias Low risk None identified.
Nosten 1994 THA
Methods Trial design: RCT
Data collected: 1987 to 1990
Length of follow-up: from first antenatal visit at > 20 weeks of estimated gestation to 2
years after delivery
Frequency of follow-up: weekly
Participants Parity: all
Number: 339
Inclusion criteria: antenatal attendees > 20 weeks of gestation
Excluded: none stated
Interventions 1. Mefloquine: weekly
2. Nothing
Other: treated antenatally if parasitaemic; given folic acid and iron if anaemic
Administration supervised: yes
Outcomes 1. Antenatal episodes of parasitaemia
2. Anaemia
3. Preterm birth
4. Birthweight
5. Perinatal death
Notes Location: Thailand
Urban/rural: rural (camps Wangka, Shoklo, Bonoko)
Malaria transmission: unstable malarious area (mesoendemic)
Drug resistance: multiple drug resistance present
Funding: United Nations Development Programme/World Bank/WHO Special Pro-
gramme for Research andTraining in Tropical Diseases;WellcomeTrust of Great Britain;
Prevention Foundation, The Hague
Risk of bias
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Nosten 1994 THA (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Trial described as “a double-blind, placebo-
controlled trial”. No details provided of the
sequence generation method used
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo tablets identical with treatments
were used.
“The investigators were unaware of the ran-
domization”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessors not men-
tioned.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition rate 8% (10/119) in Phase 1 and
8% (18/220) in Phase 2. Across groups:
7.1% (12/170) were excluded from the
mefloquine group and 9.5% (16/169) were
excluded from the placebo group. Explana-
tion provided
Selective reporting (reporting bias) Low risk No apparent risk.
Other bias Low risk None identified.
Parise 1998i KEN
Methods Trial design: Quasi-RCT
Data collected:1994 to 1996
Length of follow-up: from first antenatal visit to delivery; for infants: follow-up at 3-7
days of life and at 6 weeks of age
Frequency of follow-up: at two and four weeks after enrolment and then monthly until
delivery
Participants Parity: para 0-1
Number: 2077
Inclusion criteria: antenatal clinic attendees; first or second pregnancy
Excluded: prior ADRs to sulfa-containing or other antimalarial medications
Interventions 1. SP: treatment dose, repeated in late pregnancy (2 doses); not administered at
intervals of less than 1 month
2. No intermittent preventive treatment, SP given with recent history of fever or
parasitaemia
Other: 200 mg ferrous sulphate and 5 mg folic acid daily
Administration supervised: Yes
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Parise 1998i KEN (Continued)
Outcomes 1. Maternal anaemia
2. Mean haemoglobin
3. Placental infection
4. Birthweight
5. Preterm birth
6. Stillbirth
7. Neonatal death
Notes Location: Kenya
Urban/rural: urban
Malaria transmission: hyperendemic area
Drug resistance: chloroquine
HIV seroprevalence : 2SP - 26.9% (53/196); Case management - 26.9% (57/212)
Funding: UNDP/World Bank/WHO Special Programme for Research and Training
in Tropical Diseases (ID No. 940060); the US Agency for International Development
through theHealth andHumanResources Analysis for Africa (HHRAA) Project through
a Participating Agency Service Agreement (PASA number AOT-0483-P-HI-2171)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Womenwere systematically assigned to re-
ceive one of three regimens using a rotating
assignment based on day of clinic visit.”
Comment: allocation was not random.
Allocation concealment (selection bias) High risk Allocation schedule not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding. Women were systematically
assigned to receive either two-dose SP with
treatment doses at enrolment
and again early in the third trimester, or
case management (CM)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk “Six hundred ninety-nine women (34%)
were lost to follow-upduringpregnancy be-
cause they moved out of the study area or
failed to return for follow-up and the study
team was unable to locate their houses.”
Data was not available for 36.5% (248/
680) women in the 2 SP and 35.9% (264/
736)women in the casemanagement group
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Parise 1998i KEN (Continued)
Selective reporting (reporting bias) Low risk The trial protocol was available. No selec-
tive reporting observed
Other bias Low risk No apparent risk.
Parise 1998ii KEN
Methods As for Parise 1998i KEN
Participants As for Parise 1998i KEN
Interventions 1. SP: monthly with treatment doses at enrolment and then monthly through 34
weeks of gestation
2. No intermittent preventive treatment, SP given with recent history of fever or
parasitaemia
Outcomes As for Parise 1998i KEN
Notes As for Parise 1998i KEN
HIV seroprevalence: Monthly SP - 23.7% (40/169); Case management - 26.9% (57/
212)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Women were systematically assigned to receive one of three
regimens using a rotating assignment based on day of clinic
visit.”
Comment: allocation was not random.
Allocation concealment (selection bias) High risk Allocation schedule not concealed.
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nodetails provided as towhether the outcome assessors were
blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk Six hundred ninety-nine women (34%) were lost to fol-
low-up. Data was not available for 34.8% (230/661) in the
monthly SP and 35.9% (264/736) in the case management
group
Selective reporting (reporting bias) Low risk No selective reporting observed.
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Parise 1998ii KEN (Continued)
Other bias Low risk None identified.
Shulman 1999 KEN
Methods Trial design: RCT
Data collected: 1996 to 1997
Length of follow-up: from first antenatal visit to one month post delivery (neonatal
period)
Frequency of follow-up: unclear (drug administered as follows: three doses for women
recruited at 16 to 19 weeks of gestation; two for those recruited at 20 to 26 weeks; and
one for those recruited at 27 to 30 weeks, followed by a visit at 34 weeks and a visit 4
weeks after delivery)
Participants Parity: 0
Number: 1264
Inclusion criteria: primigravidae attending antenatal clinics at a health centre (1) or
hospital (1); singleton pregnancy; 16 to 30 weeks gestation
Excluded: severely anaemic and sick patients excluded
Interventions 1. SP: recruited at 16 to 19 weeks (2 doses); 20 to 26 weeks (2 doses); 27 to 30
weeks (1 dose)
2. Placebo
Other: ferrous sulphate; impregnated bed nets in use in the area
Administration supervised: yes
Outcomes 1. Antenatal: parasitaemia and haemoglobin at 34 weeks
2. Stillbirth
3. Neonatal death
4. Maternal death
5. Morbidity
Notes Location: Kenya
Urban/rural: rural (Kilifi)
Malaria transmission: hyperendemic and mesoendemic areas
Drug resistance: present
Funding: UK Department for International Development and KEMRI
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned unique iden-
tification numbers sequentially… identifi-
cation numbers had been randomly allo-
cated to a number between zero and nine,
in blocks of ten.”
Comment: randomization method, using
permuted blocks
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Shulman 1999 KEN (Continued)
Allocation concealment (selection bias) Low risk Drugs supplied in bottles.
“Questionnaires were premarked with this
unique identification number and the bot-
tle number. The code relating bottle num-
bers to their contents was retained by a
statistician and clinician, not involved in
the study.”
Comment: allocation concealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk SP and placebo tablets, “identical in ap-
pearance and taste”.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not clear whether outcome assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition rate 11.41% (73/640) in the SP
group and 9.5 % (59/624) in the placebo
group, signifying the number of women
with no blood test during third trimester
Selective reporting (reporting bias) Low risk Trial protocol available; no apparent risk of
selective reporting identified
Other bias Unclear risk Protocol violation: 6 women from SP
group and 8 from placebo group re-
ported taking extra doses of SP (unclear
whether women from the placebo group
took placebo tablets, or real SP)
69 women from SP group reported taking
chloroquine.
61 women from placebo group reported
taking chloroquine.
Villegas 2007 THA
Methods Trial design: RCT
Data collected: November 1998 to January 2000 (infant follow-up completed in De-
cember 2001)
Length of follow-up: Mother: from the first antenatal visit to delivery; infant follow-up
completed 1 year after delivery
Frequency of follow-up: weekly
Participants Parity: all
Number: 951
Inclusion criteria: pregnant women of all parities, of any gestational age, with a negative
malaria smear and able to comply with the trial protocol
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Villegas 2007 THA (Continued)
Excluded: allergy to chloroquine, inability to tolerate oral drugs, severe renal or hepatic
impairment, tuberculosis treatment, a history of epilepsy or diabetes mellitus or both,
or signs of labour
Interventions 1. Chloroquine: 4 tablets (250 mg chloroquine phosphate, 153 mg base) given on
enrolment. Two tablets of the same type given on a weekly basis afterwards, until
delivery.
2. Placebo
Other: ferrous sulphate + folic acid
Administration supervised: yes
Outcomes 1. Maternal mortality
2. P. vivax and P. falciparum parasitaemia
3. Anaemia
4. Birth outcomes (miscarriage, stillbirth)
5. Birthweight (mean and low birthweight)
6. Prematurity
Notes Location: Thailand
Urban/rural: rural (Maela Refugee Camp and the vicinity of Maw Ker Tai village)
Malaria transmission: low, seasonal transmission
Drug resistance: possible chloroquine resistance
HIV prevalence: no information
Funding: Wellcome Trust of Great Britain, Ministerio de Salud de Venezuela (Proyecto
Control de Enfermedades), the UNDP/World Bank/WHO Special Programme for Re-
search training in Tropical Diseases (Research Training Grant)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned unique identi-
fication numbers sequentially. All identi-
fication numbers were allocated randomly
by computer to a number between one and
ten, in blocks of ten (five randomly allo-
cated to CQ and five to placebo in each
block)”
Randomization method, using permuted
blocks.
Allocation concealment (selection bias) Low risk “Each unique identification number was
linked to a brown paper envelope which
contained the study drugs in weekly allot-
ments, sealed into zippered plastic bags…
labelled with week number of the study.
The preparation of the study drugs was
done in Mae Sot by the SMRU pharmacist
who was not involved with any other as-
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Villegas 2007 THA (Continued)
pect of the study. The study codes and ran-
domization list was retained by a clinician
at SMRU...”
Allocation was concealed.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo and active tablets, “identical in ap-
pearance and taste”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The investigators and staff participating in
the trial were unaware of the study codes
until data collection was completed.”
Outcome assessors were probably blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk A total of 49/1000 pregnant women (4.
9%), out of which 28/500 (5.6%) in the
chloroquine group and 21/500 (4.2%) in
the placebo group were excluded from the
final analysis of efficacy against P. vivax.
Reasons for exclusion were provided.
Selective reporting (reporting bias) Low risk None identified.
Other bias Low risk No apparent risk.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Asa 2008 NGA No placebo/no intervention group. Compares chloroquine with SP
Briand 2009 BEN No placebo/no intervention group. Compares SP with mefloquine
Clerk 2008 GHA No placebo/no intervention group. Compares SP with amodiaquine or amodiaquine plus SP
Deen 2001 The study is a part of a double-blinded, placebo-controlled, village-randomized malaria transmission-
reduction trial, comparing the efficacy of a single dose of artesunate and SP against placebo. However,
target group is the general population (14,017 villagers). Women who were “thought that they might
be pregnant”, were advised not to take the study drugs. Some of them unknowingly took the drugs and
their outcomes are reported. There is no specific method of randomization of the pregnant women who
“accidentally” took the drugs, to ensure similarity of the groups. Also, distribution is uneven: N = 287 in
the intervention group versus N =40 in the control group
Diakite 2011 MLI No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses
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Diallo 2007 MLI No placebo/no intervention group. Compares weekly chloroquine with intermittent SP
Dolan 1993 Trial of impregnated mosquito nets.
Filler 2006 MWI No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses
Gies 2009 Described as “a health centre randomized trial”. This study evaluated the IPT-SP uptake in a community-
based trial where health centres were randomized to one of three arms: IPT-SP with health promotion,
IPT-SP without promotion and weekly CQ. The purpose was to assess the impact of a village-based
promotional campaign to enhance antenatal clinic (ANC) attendance
Hamer 2007 ZMB No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses
Hamilton 1972 UGA This previously included trial was excluded in the updated version because Hamilton and his team ad-
ministered iron to one of the control groups and folic acid to the other, but nothing was mentioned of
iron and folates being administered to women in the intervention group (chloroquine)
Helitzer 1994 4 clinics trying different methods to achieve adherence; not randomized
Kayentao 2005 MLI No placebo/no intervention group. Compares weekly chloroquine with intermittent SP
Luntamo 2010 MWI No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses
Martin 1982 Reported as randomized 100 women, but analysis is by whether women complied, and those that did not
comply (37 participants) analysed as a separate group
McDermott 1988 Started as a RCT, but discontinued when reports elsewhere noted an association between amodiaquine
and agranulocytosis; trial then became an observational study with the 2 arms of the trial combined
McGready 2001 Trial of repellent.
Menéndez 2011 Study done in the context of a randomized, double-blind, placebo-controlled trial of IPT- SP for malaria
prevention (already included, Menendez 2008 MOZ).
Mutabingwa 1993 TZA No placebo/no intervention group. Compares weekly chloroquine with daily proguanil
Naniche 2008 Study done in the context of a randomized, double-blind, placebo-controlled trial of IPT- SP for malaria
prevention (already included, Menendez 2008 MOZ).
Ouedraogo 2008 BFA No placebo/no intervention group. Compares weekly chloroquine with intermittent SP
Pertet 1994 Possible RCT; wrote to the authors in 1998; no response.
Randriam. 2011 MDG No placebo/no intervention group. Compares weekly chloroquine with intermittent SP
Schultz 1994 MWI No placebo/no intervention group. Compares weekly chloroquine with intermittent SP
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Serra-Casas 2010 Study is done in the context of a randomized, double-blind, placebo-controlled trial of IPT- SP for
malaria prevention during pregnancy (already included, Menendez 2008 MOZ), investigating the effect
of IPT-SP on maternal and cord Immunoglobulin G (IgG) levels and comparing antibody levels between
intervention groups. The study is mostly about the association between antibody levels and morbidity
outcomes, and not focused on the specific outcomes included in the protocol for the review
Shulman 1998 Study of impregnated mosquito nets.
Steketee 1996 Comparison between mefloquine and chloroquine.
Tagbor 2010 A randomized controlled non-inferiority trial conducted in Ghana, comparing the safety and efficacy
of intermittent screening and treatment (IST), a new strategy for malaria control, and treatment with
SP. There were two intervention groups: SP and IST; IST and treatment with amodiaquine+artesunate
(AQ+AS), versus the control group - standard IPT-SP. We excluded this study because a different strategy
(not chemoprevention but early screening and treatment) was used in the intervention arm
Thaler 2006 Study, comparing riboflavin (not an active antimalarial drug) to placebo
Tukur 2007 NGA No placebo/no intervention group. Compares chloroquine once only followed by weekly pyrimethamine
with intermittent SP
Valea 2010 BFA No placebo/no intervention group. Compares intermittent SP: 2 doses versus 3 doses
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D A T A A N D A N A L Y S E S
Comparison 1. Preventive antimalarials versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death (mother) 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Para 0-1 4 2097 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.44, 3.06]
1.2 Multigravidae 1 2239 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.42, 5.21]
1.3 All women 4 6026 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.25, 2.74]
2 Severe anaemia (mother) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Para 0-1 4 2503 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.47, 0.75]
2.2 Multigravidae 2 2682 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.41, 2.25]
2.3 All women 2 1327 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.05, 0.75]
3 Anaemia (mother) 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Para 0-1 7 3662 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.74, 0.93]
3.2 All women 3 3027 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.87, 1.23]
4 Mean haemoglobin (g/dL) 10 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Baseline Hb 5 3004 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.10, 0.17]
4.2 Para 0-1 7 3363 Mean Difference (IV, Fixed, 95% CI) 0.41 [0.29, 0.54]
4.3 Multigravidae 2 676 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.23, 0.24]
4.4 All women 3 2223 Mean Difference (IV, Fixed, 95% CI) 0.13 [0.00, 0.25]
5 Clinical malaria (mother) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Para 0-1 2 307 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.18, 0.74]
5.2 All women 4 3455 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.11, 1.23]
6 Parasitaemia (mother) 13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Para 0-1 10 3663 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.26, 0.58]
6.2 Multigravidae 4 3022 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.28, 0.50]
6.3 All women 5 3961 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.44, 1.13]
7 Adverse effects with SP 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Skin reactions 2 1472 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.27, 2.65]
7.2 Nausea and vomiting 2 1472 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [0.22, 12.81]
7.3 Any other adverse effects 3 2599 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.38, 1.36]
8 Adverse effects with mefloquine 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Dizziness 1 107 Risk Ratio (M-H, Fixed, 95% CI) 1.6 [0.90, 2.83]
8.2 Vertigo 1 339 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.81, 1.28]
8.3 Vomiting 1 339 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.10]
8.4 Itching 1 339 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.73, 1.38]
8.5 Visual abnormalities 1 339 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.72, 1.39]
9 Spontaneous abortion 10 8643 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.56, 1.05]
9.1 Para 0-1 7 2876 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.41, 1.02]
9.2 All women 3 5767 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.58, 1.36]
10 Stillbirth 9 9833 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.79, 1.28]
10.1 Para 0-1 4 2703 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.63, 1.49]
10.2 All women 5 7130 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.76, 1.36]
11 Perinatal deaths 6 6836 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.81, 1.22]
11.1 Para 0-1 2 1620 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.54, 1.00]
11.2 All women 4 5216 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.94, 1.63]
12 Neonatal and infant mortality 9 10486 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.76, 1.14]
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12.1 Para 0-1 (neonatal death:
day 0-28)
3 2156 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.37, 1.05]
12.2 Para 1+ (deaths up to six
weeks)
1 2017 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.90, 2.38]
12.3 All women (neonatal and
infant death: day 0-1 year)
5 6313 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.71, 1.16]
13 Preterm birth 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Para 0-1 3 1493 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.10]
13.2 All women 2 1174 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.65, 1.38]
14 Low birthweight 13 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Para 0-1 10 3619 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.61, 0.87]
14.2 Multigravidae 3 2743 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.65, 1.15]
14.3 All women 4 3644 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.89, 1.27]
15 Mean birthweight (baby) 15 Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Para 0-1 11 3936 Mean Difference (IV, Fixed, 95% CI) 92.72 [62.05, 123.
39]
15.2 All women 5 6007 Mean Difference (IV, Fixed, 95% CI) -0.54 [-24.66, 23.
58]
16 Cord blood anaemia 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Para 0-1 1 64 Risk Ratio (M-H, Fixed, 95% CI) 2.94 [0.78, 11.05]
16.2 All women 1 870 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.30, 0.80]
17 Cord blood haemoglobin 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Para 0-1 1 64 Mean Difference (IV, Fixed, 95% CI) -1.80 [-3.46, -0.14]
17.2 All women 1 990 Mean Difference (IV, Fixed, 95% CI) 1.01 [0.05, 1.97]
18 Placental parasitemia (fetus) 13 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 Para 0-1 9 2830 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.43, 0.69]
18.2 All women 4 3200 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.15, 1.29]
19 Cord blood parasitaemia 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Para 0-1 2 1335 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.22, 1.01]
19.2 All women 1 2629 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.47, 1.14]
20 Adverse effects (baby) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Neonatal icterus 3 2233 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.13]
20.2 Congenital anomalies 2 1328 Risk Ratio (M-H, Fixed, 95% CI) 3.53 [0.58, 21.33]
Comparison 2. IPT with SP versus placebo/no intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death (mother) 3 1926 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.30, 3.22]
2 Severe anaemia (mother) 4 2503 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.47, 0.75]
3 Anaemia (mother) 5 3219 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.81, 0.96]
4 Mean haemoglobin (g/dL) 5 2995 Mean Difference (IV, Fixed, 95% CI) 0.41 [0.27, 0.54]
5 Parasitaemia (mother) 7 3456 Risk Ratio (M-H, Random, 95% CI) 0.38 [0.24, 0.59]
6 Clinical malaria (mother) 1 174 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.05, 1.12]
7 Spontaneous abortion 5 2572 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.38, 0.99]
8 Stillbirth 3 2572 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.62, 1.50]
9 Perinatal deaths 1 1237 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.52, 1.17]
10 Neonatal and infant mortality 3 2156 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.37, 1.05]
11 Preterm birth 3 1493 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.66, 1.10]
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12 Low birthweight 7 3043 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.67, 0.99]
13 Mean birthweight (baby) 6 2693 Mean Difference (IV, Fixed, 95% CI) 105.50 [68.02, 142.
98]
14 Placental parasitemia (fetus) 6 2257 Risk Ratio (M-H, Random, 95% CI) 0.45 [0.33, 0.61]
15 Cord blood parasitaemia 2 1335 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.22, 1.01]
16 Adverse effects (baby) 4 3250 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.64, 1.15]
16.1 Neonatal icterus 3 2233 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.63, 1.13]
16.2 Congenital anomalies 1 1017 Risk Ratio (M-H, Fixed, 95% CI) 2.94 [0.12, 71.90]
Analysis 1.1. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 1 Death
(mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 1 Death (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Menendez 1994 GMB (1) 3/82 2/89 25.8 % 1.63 [ 0.28, 9.50 ]
Shulman 1999 KEN (2) 1/567 4/564 53.9 % 0.25 [ 0.03, 2.22 ]
Njagi 2003i KEN (3) 2/207 0/206 6.7 % 4.98 [ 0.24, 103.02 ]
Njagi 2003ii KEN (4) 2/193 1/189 13.6 % 1.96 [ 0.18, 21.42 ]
Subtotal (95% CI) 1049 1048 100.0 % 1.15 [ 0.44, 3.06 ]
Total events: 8 (Intervention), 7 (Control)
Heterogeneity: Chi2 = 3.12, df = 3 (P = 0.37); I2 =4%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Multigravidae
Mbaye 2006 GMB (5) 6/1129 4/1110 100.0 % 1.47 [ 0.42, 5.21 ]
Subtotal (95% CI) 1129 1110 100.0 % 1.47 [ 0.42, 5.21 ]
Total events: 6 (Intervention), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
3 All women
Greenwood 1989 GMB (6) 1/518 3/531 49.6 % 0.34 [ 0.04, 3.27 ]
Nosten 1994 THA (7) 1/171 0/168 8.4 % 2.95 [ 0.12, 71.85 ]
Menendez 2008 MOZ (8) 1/515 0/515 8.4 % 3.00 [ 0.12, 73.47 ]
Ndyomugyenyi 2011 UGA (9) 1/1815 2/1793 33.7 % 0.49 [ 0.04, 5.44 ]
Subtotal (95% CI) 3019 3007 100.0 % 0.84 [ 0.25, 2.74 ]
0.01 0.1 1 10 100
Favours Intervention Favours Control
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 4 (Intervention), 5 (Control)
Heterogeneity: Chi2 = 2.00, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Chi2 = 0.42, df = 2 (P = 0.81), I2 =0.0%
0.01 0.1 1 10 100
Favours Intervention Favours Control
(1) Menendez 1994 GMB: Pyrimethamine-dapsone 12.5mg/100mg weekly
(2) Shulman 1999 KEN: SP (three doses).
(3) Njagi 2003i KEN: SP (two doses) + ITNs
(4) Njagi 2003ii KEN: SP (two doses).
(5) SP (monthly for up to four doses).
(6) Greenwood 1989 GMB: Pyrimethamine-dapsone 25mg/100mg every two weeks
(7) Nosten 1994 THA: Mefloquine weekly.
(8) Menendez 2008 MOZ: SP (two doses)
(9) Ndyomugyenyi 2011 UGA: SP (two doses)
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Analysis 1.2. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 2 Severe
anaemia (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 2 Severe anaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Para 0-1
Parise 1998i KEN (1) 11/365 10/197 7.5 % 0.59 [ 0.26, 1.37 ]
Parise 1998ii KEN (2) 9/352 10/197 6.8 % 0.50 [ 0.21, 1.22 ]
Shulman 1999 KEN (3) 82/567 134/565 85.1 % 0.61 [ 0.48, 0.78 ]
Menendez 2008 MOZ (4) 0/133 3/127 0.6 % 0.14 [ 0.01, 2.62 ]
Subtotal (95% CI) 1417 1086 100.0 % 0.60 [ 0.47, 0.75 ]
Total events: 102 (Intervention), 157 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.43 (P < 0.00001)
2 Multigravidae
Mbaye 2006 GMB (5) 105/987 86/967 79.3 % 1.20 [ 0.91, 1.57 ]
Menendez 2008 MOZ 2/360 5/368 20.7 % 0.41 [ 0.08, 2.09 ]
Subtotal (95% CI) 1347 1335 100.0 % 0.96 [ 0.41, 2.25 ]
Total events: 107 (Intervention), 91 (Control)
Heterogeneity: Tau2 = 0.22; Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.10 (P = 0.92)
3 All women
Nosten 1994 THA (6) 0/171 6/168 22.5 % 0.08 [ 0.00, 1.33 ]
Menendez 2008 MOZ (7) 2/493 8/495 77.5 % 0.25 [ 0.05, 1.18 ]
Subtotal (95% CI) 664 663 100.0 % 0.19 [ 0.05, 0.75 ]
Total events: 2 (Intervention), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 3.86, df = 2 (P = 0.15), I2 =48%
0.002 0.1 1 10 500
Favours chemoprevention Favours control
(1) Parisse 1998i KEN: SP (two doses). Severe anaemia defined as Hb<7 g/dL.
(2) Parisse 1998ii KEN: SP (monthly). Severe anaemia defined as Hb<7 g/dL.
(3) Shulman 1999 KEN: SP (three doses). Severe anaemia defined as Hb<8 g/dL
(4) Menendez 2008 MOZ: SP (two doses). Severe anaemia defined as PCV<21%
(5) Mbaye 2006 GMB: Para 1+; SP (monthly for up to four doses). Severe anaemia defined as Hb<7 g/dL
(6) Nosten 1994 THA: Mefloquine weekly. Six placebo recipients required hospital admission because of severe malaria
(7) Menendez 2008 MOZ: SP (two doses). Severe anaemia defined as PCV<21%
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Analysis 1.3. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 3 Anaemia
(mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 3 Anaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Para 0-1
Fleming 1986 NGA (1) 26/89 11/18 4.2 % 0.48 [ 0.29, 0.78 ]
Parise 1998ii KEN (2) 275/431 174/236 21.4 % 0.87 [ 0.78, 0.96 ]
Parise 1998i KEN (3) 294/432 174/236 21.8 % 0.92 [ 0.84, 1.02 ]
Shulman 1999 KEN (4) 431/567 460/565 24.5 % 0.93 [ 0.88, 0.99 ]
Ndyomugyenyi 2000 UGA (5) 43/168 64/168 8.1 % 0.67 [ 0.49, 0.93 ]
Njagi 2003ii KEN (6) 51/183 80/175 9.6 % 0.61 [ 0.46, 0.81 ]
Njagi 2003i KEN (7) 67/198 72/196 10.3 % 0.92 [ 0.70, 1.20 ]
Subtotal (95% CI) 2068 1594 100.0 % 0.83 [ 0.74, 0.93 ]
Total events: 1187 (Intervention), 1035 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 20.65, df = 6 (P = 0.002); I2 =71%
Test for overall effect: Z = 3.29 (P = 0.0010)
2 All women
Nosten 1994 THA (8) 98/159 103/152 41.0 % 0.91 [ 0.77, 1.07 ]
Menendez 2008 MOZ (9) 95/416 89/432 26.6 % 1.11 [ 0.86, 1.43 ]
Ndyomugyenyi 2011 UGA (10) 149/915 135/953 32.4 % 1.15 [ 0.93, 1.42 ]
Subtotal (95% CI) 1490 1537 100.0 % 1.03 [ 0.87, 1.23 ]
Total events: 342 (Intervention), 327 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.01, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 4.45, df = 1 (P = 0.03), I2 =78%
0.5 0.7 1 1.5 2
Favours chemoprevention Favours control
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(1) Fleming 1986 NGA: Proguanil 100 mg daily. Anaemia defined as Hb<12.0 g/dL
(2) Parisse 1998ii KEN: SP (monthly). Anaemia defined as Hb≤11 g/dL.
(3) Parisse 1998i KEN: SP (two doses). Anaemia defined as Hb≤11 g/dL.
(4) Shulman 1999 KEN: SP (three doses). Anaemia defined as Hb < 11 g/dL
(5) Ndyomugyenyi 2000 UGA: Chloroquine 300mg weekly. Anaemia defined as Hb<10.0 g/dL
(6) Njagi 2003ii KEN: SP (two doses). Anaemia defined as Hb<10.0 g/dL
(7) Njagi 2003i KEN: SP (two doses) + ITNs. Anaemia defined as Hb<10.0 g/dL
(8) Nosten 1994 THA: Mefloquine (weekly). Anaemia defined as PCV<30%
(9) Menendez 2008 MOZ: SP (two doses). Anaemia defined as PCV<33% measured 2 months after delivery.
(10) Ndyomugyenyi 2011 UGA: SP (two doses). Anaemia defined as Hb < 11 g/dL
Analysis 1.4. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 4 Mean
haemoglobin (g/dL).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 4 Mean haemoglobin (g/dL)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Baseline Hb
Parise 1998i KEN (1) 680 9.6 (1.9) 368 9.6 (1.9) 31.9 % 0.0 [ -0.24, 0.24 ]
Parise 1998ii KEN (2) 661 9.7 (1.9) 368 9.6 (1.9) 31.6 % 0.10 [ -0.14, 0.34 ]
Ndyomugyenyi 2000 UGA (3) 85 9.6 (1.46) 90 10.18 (1.68) 8.5 % -0.58 [ -1.05, -0.11 ]
Njagi 2003i KEN (4) 198 10.5 (1.8) 196 10.5 (1.9) 13.9 % 0.0 [ -0.37, 0.37 ]
Njagi 2003ii KEN (5) 183 10.7 (1.7) 175 10.3 (1.8) 14.1 % 0.40 [ 0.04, 0.76 ]
Subtotal (95% CI) 1807 1197 100.0 % 0.04 [ -0.10, 0.17 ]
Heterogeneity: Chi2 = 10.98, df = 4 (P = 0.03); I2 =64%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Para 0-1
Greenwood 1989 GMB (6) 21 10.03 (1.56) 11 9.53 (1.1) 1.7 % 0.50 [ -0.43, 1.43 ]
-2 -1 0 1 2
Favours Control Favours Chemoprevention
(Continued . . . )
75Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(. . . Continued)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parise 1998i KEN 365 10.2 (1.7) 197 9.9 (1.7) 17.4 % 0.30 [ 0.01, 0.59 ]
Parise 1998ii KEN 352 10.4 (1.8) 197 9.9 (1.7) 16.5 % 0.50 [ 0.20, 0.80 ]
Shulman 1999 KEN (7) 567 9.7 (1.76) 565 9.3 (1.85) 34.1 % 0.40 [ 0.19, 0.61 ]
Ndyomugyenyi 2000 UGA 168 10.96 (1.7) 168 10.51 (1.5) 12.8 % 0.45 [ 0.11, 0.79 ]
Njagi 2003ii KEN 183 11 (1.9) 175 10.3 (2.2) 8.3 % 0.70 [ 0.27, 1.13 ]
Njagi 2003i KEN 198 10.8 (2) 196 10.6 (2.1) 9.2 % 0.20 [ -0.21, 0.61 ]
Subtotal (95% CI) 1854 1509 100.0 % 0.41 [ 0.29, 0.54 ]
Heterogeneity: Chi2 = 3.78, df = 6 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 6.60 (P < 0.00001)
3 Multigravidae
Greenwood 1989 GMB 126 10.2 (1.3) 118 10.1 (1.3) 52.8 % 0.10 [ -0.23, 0.43 ]
Mbaye 2006 GMB (8) 213 8.9 (1.83) 219 9 (1.83) 47.2 % -0.10 [ -0.45, 0.25 ]
Subtotal (95% CI) 339 337 100.0 % 0.01 [ -0.23, 0.24 ]
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
4 All women
Greenwood 1989 GMB (9) 126 10.2 (1.3) 118 10.1 (1.3) 14.5 % 0.10 [ -0.23, 0.43 ]
Greenwood 1989 GMB (10) 21 10.03 (1.56) 11 9.53 (1.1) 1.8 % 0.50 [ -0.43, 1.43 ]
Nosten 1994 THA (11) 43 11.46 (1.23) 43 10.6 (1) 6.9 % 0.86 [ 0.39, 1.33 ]
Ndyomugyenyi 2011 UGA (12) 946 12.5 (1.56) 915 12.44 (1.56) 76.8 % 0.06 [ -0.08, 0.20 ]
Subtotal (95% CI) 1136 1087 100.0 % 0.13 [ 0.00, 0.25 ]
Heterogeneity: Chi2 = 10.69, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.03 (P = 0.042)
Test for subgroup differences: Chi2 = 20.76, df = 3 (P = 0.00), I2 =86%
-2 -1 0 1 2
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(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Ndyomugyenyi 2000 UGA: Chloroquine 300mg weekly.
(4) Njagi 2003i KEN: SP (two doses) + ITNs
(5) Njagi 2003ii KEN: SP (two doses).
(6) Greenwood 1989 GMB: Pyrimethamine-dapsone 25mg/100mg every two weeks
(7) Shulman 1999 KEN: SP (three doses).
(8) Mbaye 2006 GMB: SP (monthly for up to four doses). (Hb of participants who did not report use of bednets)
(9) Greenwood 1989 GMB: Multigravidae
(10) Greenwood 1989 GMB: Para 0-1
(11) Nosten 1994 THA: Mefloquine weekly.
(12) Ndyomugyenyi 2011 UGA: SP (two doses).
Analysis 1.5. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 5 Clinical
malaria (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 5 Clinical malaria (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Para 0-1
Cot 1995 CMR (1) 7/63 19/70 78.5 % 0.41 [ 0.18, 0.91 ]
Challis 2004 MOZ (2) 2/88 8/86 21.5 % 0.24 [ 0.05, 1.12 ]
Subtotal (95% CI) 151 156 100.0 % 0.37 [ 0.18, 0.74 ]
Total events: 9 (Intervention), 27 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 All women
Morley 1964 NGA (3) 0/119 14/108 11.8 % 0.03 [ 0.00, 0.52 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Nosten 1994 THA (4) 5/167 37/170 28.2 % 0.14 [ 0.06, 0.34 ]
Menendez 2008 MOZ (5) 36/515 51/515 32.4 % 0.71 [ 0.47, 1.06 ]
Ndyomugyenyi 2011 UGA (6) 10/946 7/915 27.6 % 1.38 [ 0.53, 3.61 ]
Subtotal (95% CI) 1747 1708 100.0 % 0.37 [ 0.11, 1.23 ]
Total events: 51 (Intervention), 109 (Control)
Heterogeneity: Tau2 = 1.11; Chi2 = 19.32, df = 3 (P = 0.00024); I2 =84%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours chemoprevention Favours control
(1) Cot 1995 CMR: Chloroquine (300mg weekly).
(2) Challis 2004 MOZ: SP (two doses).
(3) Morley 1964 NGA: Pyrimethamine (100mg monthly).
(4) Nosten 1994 THA: Mefloquine (weekly).
(5) Menendez 2008 MOZ: SP (two doses)
(6) Ndyomugyenyi 2011 UGA: SP (two doses)
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Analysis 1.6. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 6
Parasitaemia (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 6 Parasitaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Para 0-1
Fleming 1986 NGA (1) 2/106 5/22 4.5 % 0.08 [ 0.02, 0.40 ]
Greenwood 1989 GMB (2) 4/21 5/13 6.7 % 0.50 [ 0.16, 1.52 ]
Nahlen 1989 NGA (3) 6/23 6/22 7.7 % 0.96 [ 0.36, 2.52 ]
Parise 1998i KEN (4) 34/348 48/178 12.0 % 0.36 [ 0.24, 0.54 ]
Parise 1998ii KEN (5) 22/327 48/177 11.5 % 0.25 [ 0.16, 0.40 ]
Shulman 1999 KEN (6) 30/567 199/564 12.2 % 0.15 [ 0.10, 0.22 ]
Njagi 2003i KEN (7) 28/172 35/170 11.6 % 0.79 [ 0.50, 1.24 ]
Njagi 2003ii KEN (8) 22/148 45/134 11.6 % 0.44 [ 0.28, 0.70 ]
Challis 2004 MOZ (9) 18/208 40/203 11.1 % 0.44 [ 0.26, 0.74 ]
Menendez 2008 MOZ (10) 18/133 30/127 11.0 % 0.57 [ 0.34, 0.97 ]
Subtotal (95% CI) 2053 1610 100.0 % 0.39 [ 0.26, 0.58 ]
Total events: 184 (Intervention), 461 (Control)
Heterogeneity: Tau2 = 0.32; Chi2 = 49.44, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 4.54 (P < 0.00001)
2 Multigravidae
Greenwood 1989 GMB 9/120 21/103 14.7 % 0.37 [ 0.18, 0.77 ]
Nahlen 1989 NGA 2/11 5/15 3.8 % 0.55 [ 0.13, 2.31 ]
Mbaye 2006 GMB (11) 34/1035 91/1010 54.0 % 0.36 [ 0.25, 0.54 ]
Menendez 2008 MOZ 17/360 45/368 27.5 % 0.39 [ 0.23, 0.66 ]
Subtotal (95% CI) 1526 1496 100.0 % 0.38 [ 0.28, 0.50 ]
Total events: 62 (Intervention), 162 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 6.78 (P < 0.00001)
3 All women
Greenwood 1989 GMB (12) 13/141 26/116 18.4 % 0.41 [ 0.22, 0.76 ]
Nahlen 1989 NGA (13) 8/34 11/37 15.5 % 0.79 [ 0.36, 1.73 ]
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Villegas 2007 THA (14) 22/472 26/479 19.6 % 0.86 [ 0.49, 1.49 ]
Menendez 2008 MOZ (15) 35/493 75/495 22.8 % 0.47 [ 0.32, 0.69 ]
Ndyomugyenyi 2011 UGA (16) 75/853 60/841 23.7 % 1.23 [ 0.89, 1.71 ]
Subtotal (95% CI) 1993 1968 100.0 % 0.70 [ 0.44, 1.13 ]
Total events: 153 (Intervention), 198 (Control)
Heterogeneity: Tau2 = 0.22; Chi2 = 18.61, df = 4 (P = 0.00094); I2 =79%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 5.21, df = 2 (P = 0.07), I2 =62%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Fleming 1986 NGA: Proguanil 100 mg daily. Parasitaemia at 36 weeks of gestation
(2) Greenwood 1989 GMB: Pyrimethamine-dapsone (25mg/100mg every two weeks)
(3) Nahlen 1989 NGA: Pyrimethamine (25mg weekly).
(4) Parise 1998i KEN: SP (two doses). Parasitemia at delivery
(5) Parise 1998ii KEN: SP (monthly). Parasitaemia at delivery
(6) Shulman 1999 KEN: SP (three doses). Malaria parasitaemia assessed at 34 weeks of gestation
(7) Njagi 2003i KEN: SP (two doses)+ ITNs.
(8) Njagi 2003ii KEN: SP (two doses).
(9) Challis 2004 MOZ: SP (two doses). Parasitaemia measured at the beginning of the third tirmester
(10) Menendez 2008 MOZ: SP (two doses). Parasitaemia at delivery
(11) Mbaye 2006 GMB: SP (monthly for up to four doses). Parasitaemia assessed in the first week post-partum
(12) Greenwood 1989 GMB: Pyrimethamine-dapsone (25mg/100mg every two weeks)
(13) Nahlen 1989 NGA: Pyrimethamine (25mg weekly).
(14) Villegas 2007 THA: Chloroquine (300mg weekly). Parasitaemia at delivery
(15) Menendez 2008 MOZ: SP (two doses). Parasitaemia at delivery
(16) Ndyomugyenyi 2011 UGA: SP (two doses). Parasitaemia at 36-40 weeks (control had ITNs)
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Analysis 1.7. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 7 Adverse
effects with SP.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 7 Adverse effects with SP
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Skin reactions
Challis 2004 MOZ (1) 0/218 2/224 38.1 % 0.21 [ 0.01, 4.26 ]
Menendez 2008 MOZ (2) 5/515 4/515 61.9 % 1.25 [ 0.34, 4.63 ]
Subtotal (95% CI) 733 739 100.0 % 0.85 [ 0.27, 2.65 ]
Total events: 5 (Intervention), 6 (Control)
Heterogeneity: Chi2 = 1.18, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Nausea and vomiting
Challis 2004 MOZ 1/218 1/224 66.4 % 1.03 [ 0.06, 16.32 ]
Menendez 2008 MOZ 1/515 0/515 33.6 % 3.00 [ 0.12, 73.47 ]
Subtotal (95% CI) 733 739 100.0 % 1.69 [ 0.22, 12.81 ]
Total events: 2 (Intervention), 1 (Control)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
3 Any other adverse effects
Parise 1998i KEN (3) 10/432 7/236 42.8 % 0.78 [ 0.30, 2.02 ]
Parise 1998ii KEN (4) 6/431 7/236 42.8 % 0.47 [ 0.16, 1.38 ]
Shulman 1999 KEN (5) 4/640 3/624 14.4 % 1.30 [ 0.29, 5.78 ]
Subtotal (95% CI) 1503 1096 100.0 % 0.72 [ 0.38, 1.36 ]
Total events: 20 (Intervention), 17 (Control)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Chi2 = 0.64, df = 2 (P = 0.73), I2 =0.0%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Challis 2004 MOZ: SP (two doses). Urticaria
(2) Menendez 2008 MOZ: SP (two doses)
(3) Parise 1998i KEN: SP (two doses).
(4) Parise 1998ii KEN: SP (monthly). Adverse effects: nausea, vomiting, rash, pruritus, fatigue, oral lesions (resolved by the time of follow-up)
(5) Shulman 1999 KEN: SP (three doses). Drug suspended due to minor adverse drug reactions
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Analysis 1.8. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 8 Adverse
effects with mefloquine.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 8 Adverse effects with mefloquine
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dizziness
Nosten 1994 THA (1) 22/55 13/52 100.0 % 1.60 [ 0.90, 2.83 ]
Subtotal (95% CI) 55 52 100.0 % 1.60 [ 0.90, 2.83 ]
Total events: 22 (Intervention), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 Vertigo
Nosten 1994 THA 80/171 77/168 100.0 % 1.02 [ 0.81, 1.28 ]
Subtotal (95% CI) 171 168 100.0 % 1.02 [ 0.81, 1.28 ]
Total events: 80 (Intervention), 77 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
3 Vomiting
Nosten 1994 THA 39/171 50/168 100.0 % 0.77 [ 0.53, 1.10 ]
Subtotal (95% CI) 171 168 100.0 % 0.77 [ 0.53, 1.10 ]
Total events: 39 (Intervention), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
4 Itching
Nosten 1994 THA 53/171 52/168 100.0 % 1.00 [ 0.73, 1.38 ]
Subtotal (95% CI) 171 168 100.0 % 1.00 [ 0.73, 1.38 ]
Total events: 53 (Intervention), 52 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
5 Visual abnormalities
Nosten 1994 THA 51/171 50/168 100.0 % 1.00 [ 0.72, 1.39 ]
Subtotal (95% CI) 171 168 100.0 % 1.00 [ 0.72, 1.39 ]
Total events: 51 (Intervention), 50 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi2 = 4.72, df = 4 (P = 0.32), I2 =15%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Nosten 1994 THA: Mefloquine (weekly).
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Analysis 1.9. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 9
Spontaneous abortion.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 9 Spontaneous abortion
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Menendez 1994 GMB (1) 3/82 1/89 1.1 % 3.26 [ 0.35, 30.68 ]
Cot 1995 CMR (2) 0/63 2/70 2.6 % 0.22 [ 0.01, 4.54 ]
Parise 1998ii KEN (3) 9/431 5/236 7.2 % 0.99 [ 0.33, 2.91 ]
Parise 1998i KEN (4) 5/432 5/236 7.2 % 0.55 [ 0.16, 1.87 ]
Njagi 2003i KEN (5) 7/207 10/206 11.2 % 0.70 [ 0.27, 1.79 ]
Njagi 2003ii KEN (6) 8/193 13/189 14.6 % 0.60 [ 0.26, 1.42 ]
Challis 2004 MOZ (7) 0/218 5/224 6.0 % 0.09 [ 0.01, 1.68 ]
Subtotal (95% CI) 1626 1250 49.9 % 0.65 [ 0.41, 1.02 ]
Total events: 32 (Intervention), 41 (Control)
Heterogeneity: Chi2 = 4.91, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.88 (P = 0.061)
2 All women
Cot 1992 BFA (8) 6/610 5/567 5.8 % 1.12 [ 0.34, 3.63 ]
Menendez 2008 MOZ (9) 4/515 6/515 6.7 % 0.67 [ 0.19, 2.35 ]
Ndyomugyenyi 2011 UGA (10) 30/1767 34/1793 37.6 % 0.90 [ 0.55, 1.46 ]
Subtotal (95% CI) 2892 2875 50.1 % 0.89 [ 0.58, 1.36 ]
Total events: 40 (Intervention), 45 (Control)
Heterogeneity: Chi2 = 0.34, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 4518 4125 100.0 % 0.77 [ 0.56, 1.05 ]
Total events: 72 (Intervention), 86 (Control)
Heterogeneity: Chi2 = 5.95, df = 9 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
0.005 0.1 1 10 200
Favours chemoprevention Favours control
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(1) Menendez 1994 GMB: Pyrimethamine-dapsone 12.5mg/100mg weekly
(2) Cot 1995 CMR: Chloroquine (300mg weekly)
(3) Parise 1998ii KEN: SP (monthly).
(4) Parise 1998i KEN: SP (two doses).
(5) Njagi 2003i KEN: SP (two doses) + ITNs
(6) Njagi 2003ii KEN: SP (two doses).
(7) Challis 2004 MOZ: SP (two doses).
(8) Cot 1992 BFA: Chloroquine (300mg weekly).
(9) Menendez 2008 MOZ: SP (two doses)
(10) Ndyomugyenyi 2011 UGA: SP (two doses)
Analysis 1.10. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 10
Stillbirth.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 10 Stillbirth
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Cot 1995 CMR (1) 2/63 2/68 1.5 % 1.08 [ 0.16, 7.43 ]
Parise 1998i KEN (2) 11/432 5/236 5.0 % 1.20 [ 0.42, 3.42 ]
Parise 1998ii KEN (3) 9/431 5/236 5.0 % 0.99 [ 0.33, 2.91 ]
Shulman 1999 KEN (4) 24/626 26/611 20.3 % 0.90 [ 0.52, 1.55 ]
Subtotal (95% CI) 1552 1151 31.8 % 0.97 [ 0.63, 1.49 ]
Total events: 46 (Intervention), 38 (Control)
Heterogeneity: Chi2 = 0.25, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 All women
Greenwood 1989 GMB (5) 19/518 32/531 24.4 % 0.61 [ 0.35, 1.06 ]
Cot 1992 BFA (6) 13/617 11/573 8.8 % 1.10 [ 0.50, 2.43 ]
0.005 0.1 1 10 200
Favours chemoprevention Favours control
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Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Nosten 1994 THA (7) 11/159 4/152 3.2 % 2.63 [ 0.86, 8.08 ]
Menendez 2008 MOZ (8) 14/511 11/509 8.5 % 1.27 [ 0.58, 2.77 ]
Ndyomugyenyi 2011 UGA (9) 34/1793 30/1767 23.3 % 1.12 [ 0.69, 1.82 ]
Subtotal (95% CI) 3598 3532 68.2 % 1.02 [ 0.76, 1.36 ]
Total events: 91 (Intervention), 88 (Control)
Heterogeneity: Chi2 = 6.53, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.14 (P = 0.89)
Total (95% CI) 5150 4683 100.0 % 1.01 [ 0.79, 1.28 ]
Total events: 137 (Intervention), 126 (Control)
Heterogeneity: Chi2 = 6.80, df = 8 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 0.04, df = 1 (P = 0.84), I2 =0.0%
0.005 0.1 1 10 200
Favours chemoprevention Favours control
(1) Cot 1995 CMR: Chloroquine (300mg weekly)
(2) Parise 1998i KEN: SP (two doses).
(3) Parise 1998ii KEN: SP (monthly).
(4) Shulman 1999 KEN: SP (three doses).
(5) Greenwood 1989 GMB: Pyrimethamine-dapsone (25mg/100mg every two weeks)
(6) Cot 1992 BFA: Chloroquine (300mg weekly).
(7) Nosten 1994 THA: Mefloquine (weekly).
(8) Menendez 2008 MOZ: SP (two doses)
(9) Ndyomugyenyi 2011 UGA: SP (two doses).
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Analysis 1.11. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 11
Perinatal deaths.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 11 Perinatal deaths
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Greenwood 1989 GMB (1) 23/193 34/190 19.7 % 0.67 [ 0.41, 1.09 ]
Shulman 1999 KEN (2) 39/626 49/611 28.6 % 0.78 [ 0.52, 1.17 ]
Subtotal (95% CI) 819 801 48.3 % 0.73 [ 0.54, 1.00 ]
Total events: 62 (Intervention), 83 (Control)
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
2 All women
Morley 1964 NGA (3) 14/210 13/209 7.5 % 1.07 [ 0.52, 2.22 ]
Nosten 1994 THA (4) 11/159 3/152 1.8 % 3.51 [ 1.00, 12.32 ]
Menendez 2008 MOZ (5) 14/494 16/496 9.2 % 0.88 [ 0.43, 1.78 ]
Ndyomugyenyi 2011 UGA (6) 72/1737 58/1759 33.2 % 1.26 [ 0.90, 1.77 ]
Subtotal (95% CI) 2600 2616 51.7 % 1.24 [ 0.94, 1.63 ]
Total events: 111 (Intervention), 90 (Control)
Heterogeneity: Chi2 = 3.70, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 1.54 (P = 0.12)
Total (95% CI) 3419 3417 100.0 % 0.99 [ 0.81, 1.22 ]
Total events: 173 (Intervention), 173 (Control)
Heterogeneity: Chi2 = 9.85, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 0.06 (P = 0.96)
Test for subgroup differences: Chi2 = 6.22, df = 1 (P = 0.01), I2 =84%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Greenwood 1989 GMB: Pyrimethamine-dapsone (25mg/100mg every two weeks).
(2) Shulman 1999 KEN: SP (three doses).
(3) Morley 1964 NGA: Pyrimethamine (100mg monthly).
(4) Nosten 1994 THA: Mefloquine (weekly).
(5) Menendez 2008 MOZ: SP (two doses)
(6) Ndyomugyenyi 2011 UGA: SP (two doses).
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Analysis 1.12. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 12
Neonatal and infant mortality.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 12 Neonatal and infant mortality
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1 (neonatal death: day 0-28)
Parise 1998ii KEN (1) 1/327 2/168 1.4 % 0.26 [ 0.02, 2.81 ]
Parise 1998i KEN (2) 4/306 2/168 1.3 % 1.10 [ 0.20, 5.93 ]
Shulman 1999 KEN (3) 19/602 30/585 15.8 % 0.62 [ 0.35, 1.08 ]
Subtotal (95% CI) 1235 921 18.5 % 0.62 [ 0.37, 1.05 ]
Total events: 24 (Intervention), 34 (Control)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
2 Para 1+ (deaths up to six weeks)
Mbaye 2006 GMB (4) 39/1022 26/995 13.7 % 1.46 [ 0.90, 2.38 ]
Subtotal (95% CI) 1022 995 13.7 % 1.46 [ 0.90, 2.38 ]
Total events: 39 (Intervention), 26 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
3 All women (neonatal and infant death: day 0-1 year)
Morley 1964 NGA (5) 14/210 13/209 6.8 % 1.07 [ 0.52, 2.22 ]
Greenwood 1989 GMB (6) 18/518 24/531 12.3 % 0.77 [ 0.42, 1.40 ]
Nosten 1994 THA (7) 25/144 24/144 12.5 % 1.04 [ 0.63, 1.74 ]
Menendez 2008 MOZ (8) 23/497 35/500 18.1 % 0.66 [ 0.40, 1.10 ]
Ndyomugyenyi 2011 UGA (9) 38/1767 35/1793 18.1 % 1.10 [ 0.70, 1.74 ]
Subtotal (95% CI) 3136 3177 67.8 % 0.91 [ 0.71, 1.16 ]
Total events: 118 (Intervention), 131 (Control)
Heterogeneity: Chi2 = 2.95, df = 4 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 5393 5093 100.0 % 0.93 [ 0.76, 1.14 ]
Total events: 181 (Intervention), 191 (Control)
Heterogeneity: Chi2 = 9.46, df = 8 (P = 0.31); I2 =15%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 5.60, df = 2 (P = 0.06), I2 =64%
0.005 0.1 1 10 200
Favours chemoprevention Favours control
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(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
(3) Shulman 1999 KEN: SP (three doses).
(4) Mbaye 2006 GMB: SP (monthly for up to four doses).
(5) Morley 1964 NGA: Pyrimethamine (100mg monthly): neonatal death
(6) Greenwood 1989 GMB: Pyrimethamine-dapsone (25mg/100mg every two weeks): neonatal death
(7) Nosten 1994 THA: Mefloquine (weekly): Infant death
(8) Menendez 2008 MOZ: SP (two doses): infant death
(9) Ndyomugyenyi 2011 UGA: SP (two doses): neonatal death
Analysis 1.13. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 13 Preterm
birth.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 13 Preterm birth
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Parise 1998ii KEN (1) 42/350 22/180 26.6 % 0.98 [ 0.61, 1.59 ]
Parise 1998i KEN (2) 35/341 22/180 26.4 % 0.84 [ 0.51, 1.39 ]
Challis 2004 MOZ (3) 40/218 52/224 47.0 % 0.79 [ 0.55, 1.14 ]
Subtotal (95% CI) 909 584 100.0 % 0.85 [ 0.66, 1.10 ]
Total events: 117 (Intervention), 96 (Control)
Heterogeneity: Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
2 All women
Nosten 1994 THA (4) 4/102 8/97 16.1 % 0.48 [ 0.15, 1.53 ]
Ndyomugyenyi 2011 UGA (5) 45/495 42/480 83.9 % 1.04 [ 0.70, 1.55 ]
Subtotal (95% CI) 597 577 100.0 % 0.95 [ 0.65, 1.38 ]
Total events: 49 (Intervention), 50 (Control)
Heterogeneity: Chi2 = 1.54, df = 1 (P = 0.21); I2 =35%
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Chi2 = 0.20, df = 1 (P = 0.65), I2 =0.0%
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(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
(3) Challis 2004 MOZ: SP (two doses).
(4) Nosten 1994 THA: Mefloquine (weekly).
(5) Ndyomugyenyi 2011 UGA: SP (two doses).
Analysis 1.14. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 14 Low
birthweight.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 14 Low birthweight
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Greenwood 1989 GMB (1) 4/67 11/50 5.3 % 0.27 [ 0.09, 0.80 ]
Cot 1995 CMR (2) 6/57 18/65 7.1 % 0.38 [ 0.16, 0.89 ]
Parise 1998ii KEN (3) 26/331 26/170 14.6 % 0.51 [ 0.31, 0.86 ]
Parise 1998i KEN (4) 27/325 26/170 14.5 % 0.54 [ 0.33, 0.90 ]
Ndyomugyenyi 2000 UGA (5) 7/169 15/168 6.4 % 0.46 [ 0.19, 1.11 ]
Njagi 2003i KEN (6) 25/193 22/189 9.4 % 1.11 [ 0.65, 1.90 ]
Njagi 2003ii KEN (7) 21/176 29/170 12.5 % 0.70 [ 0.42, 1.18 ]
Challis 2004 MOZ (8) 19/200 27/203 11.4 % 0.71 [ 0.41, 1.24 ]
Menendez 2008 MOZ (9) 29/133 25/121 11.1 % 1.06 [ 0.66, 1.70 ]
Ndyomugyenyi 2011 UGA (10) 27/333 18/329 7.7 % 1.48 [ 0.83, 2.64 ]
Subtotal (95% CI) 1984 1635 100.0 % 0.73 [ 0.61, 0.87 ]
Total events: 191 (Intervention), 217 (Control)
Heterogeneity: Chi2 = 20.13, df = 9 (P = 0.02); I2 =55%
Test for overall effect: Z = 3.41 (P = 0.00065)
2 Multigravidae
Mbaye 2006 GMB (11) 40/738 46/716 48.6 % 0.84 [ 0.56, 1.27 ]
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(. . . Continued)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Menendez 2008 MOZ (12) 29/361 34/375 34.7 % 0.89 [ 0.55, 1.42 ]
Ndyomugyenyi 2011 UGA 14/276 16/277 16.6 % 0.88 [ 0.44, 1.76 ]
Subtotal (95% CI) 1375 1368 100.0 % 0.86 [ 0.65, 1.15 ]
Total events: 83 (Intervention), 96 (Control)
Heterogeneity: Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
3 All women
Cot 1992 BFA (13) 97/595 91/554 46.1 % 0.99 [ 0.76, 1.29 ]
Nosten 1994 THA (14) 24/146 17/144 8.4 % 1.39 [ 0.78, 2.48 ]
Menendez 2008 MOZ (15) 58/494 59/496 28.8 % 0.99 [ 0.70, 1.39 ]
Ndyomugyenyi 2011 UGA (16) 41/609 34/606 16.7 % 1.20 [ 0.77, 1.86 ]
Subtotal (95% CI) 1844 1800 100.0 % 1.06 [ 0.89, 1.27 ]
Total events: 220 (Intervention), 201 (Control)
Heterogeneity: Chi2 = 1.57, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 8.28, df = 2 (P = 0.02), I2 =76%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Greenwood 1989 GMB: Pyrimethamine-dapsone 25mg/100mg every two weeks
(2) Cot 1995 CMR: Chloroquine (300mg weekly)
(3) Parise 1998ii KEN: SP (monthly).
(4) Parise 1998i KEN: SP (two doses).
(5) Ndyomugyenyi 2000 UGA: Chloroquine 300mg weekly.
(6) Njagi 2003ii KEN: SP (two doses) + ITNs.
(7) Njagi 2003ii KEN: SP (two doses).
(8) Challis 2004 MOZ: SP (two doses).
(9) Menendez 2008 MOZ: SP (two doses)
(10) Ndyomugyenyi 2011 UGA: SP (two doses).
(11) Mbaye 2006 GMB: Para 1+; SP (monthly for up to four doses).
(12) Menendez 2008 MOZ: Para 1+
(13) Cot 1992 BFA: Chloroquine (300mg weekly).
(14) Nosten 1994 THA: Mefloquine weekly.
(15) Menendez 2008 MOZ: SP (two doses)
(16) Ndyomugyenyi 2011 UGA: SP (two doses).
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Analysis 1.15. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 15 Mean
birthweight (baby).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 15 Mean birthweight (baby)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Para 0-1
Fleming 1986 NGA (1) 128 2855 (500) 32 2723 (500) 2.5 % 132.00 [ -61.69, 325.69 ]
Greenwood 1989 GMB (2) 67 2872 (330) 50 2726 (465) 4.1 % 146.00 [ -5.18, 297.18 ]
Menendez 1994 GMB (3) 87 3028 (414) 95 2875 (430) 6.3 % 153.00 [ 30.34, 275.66 ]
Cot 1995 CMR (4) 57 3069.8 (669.9) 65 2862.3 (718.7) 1.5 % 207.50 [ -39.02, 454.02 ]
Parise 1998ii KEN (5) 331 3198 (528) 170 3079 (585) 8.6 % 119.00 [ 14.27, 223.73 ]
Parise 1998i KEN (6) 325 3183 (534) 170 3079 (585) 8.5 % 104.00 [ -1.37, 209.37 ]
Ndyomugyenyi 2000 UGA (7) 284 3009 (350) 282 2848 (500) 18.6 % 161.00 [ 89.85, 232.15 ]
Njagi 2003i KEN (8) 193 2961 (477) 189 2975 (446) 11.0 % -14.00 [ -106.58, 78.58 ]
Njagi 2003ii KEN (9) 176 2991 (418) 170 2908 (457) 11.0 % 83.00 [ -9.37, 175.37 ]
Challis 2004 MOZ (10) 200 3077 (533) 203 2926 (494) 9.3 % 151.00 [ 50.63, 251.37 ]
Ndyomugyenyi 2011 UGA (11) 333 3.124 (471) 329 3.17 (462) 18.6 % -0.05 [ -71.12, 71.02 ]
Subtotal (95% CI) 2181 1755 100.0 % 92.72 [ 62.05, 123.39 ]
Heterogeneity: Chi2 = 19.21, df = 10 (P = 0.04); I2 =48%
Test for overall effect: Z = 5.93 (P < 0.00001)
2 All women
Morley 1964 NGA (12) 196 2954 (500) 196 2797 (500) 5.9 % 157.00 [ 58.01, 255.99 ]
Nosten 1994 THA (13) 170 2877 (433) 169 2957 (475) 6.2 % -80.00 [ -176.77, 16.77 ]
Cot 1992 BFA (14) 594 2937.8 (651.5) 554 2932.2 (467.4) 13.7 % 5.60 [ -59.67, 70.87 ]
Menendez 2008 MOZ (15) 494 3033 (477.11) 496 3003.55 (522.69) 15.0 % 29.45 [ -32.89, 91.79 ]
Ndyomugyenyi 2011 UGA 1561 3144 (444) 1577 3161 (452) 59.2 % -17.00 [ -48.35, 14.35 ]
Subtotal (95% CI) 3015 2992 100.0 % -0.54 [ -24.66, 23.58 ]
Heterogeneity: Chi2 = 14.30, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 21.95, df = 1 (P = 0.00), I2 =95%
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(1) Fleming 1986 NGA: Proguanil 100 mg daily. SD estimated at 500 g
(2) Greenwood 1989 GMB: Pyrimethamine-dapsone 25mg/100mg every two weeks
(3) Menendez 1994 GMB: Pyrimethamine-dapsone 12.5mg/100mg weekly
(4) Cot 1995 CMR: Chloroquine (300mg weekly)
(5) Parise 1998ii KEN: SP (monthly).
(6) Parisse 1998i KEN: SP (two doses).
(7) Ndyomugyenyi 2000 UGA: Chloroquine 300mg weekly.
(8) Njagi 2003i KEN: SP (two doses) + ITNs
(9) Njagi 2003ii KEN: SP (two doses).
(10) Challis 2004 MOZ: SP (two doses).
(11) Ndyomugyenyi 2011 UGA: SP (two doses).
(12) Morley 1964 NGA: Pyrimethamine (100mg monthly). (an estimate of 500 g used for SD which was not reported)
(13) Nosten 1994 THA: Mefloquine weekly.
(14) Cot 1992 BFA: Chloroquine (300mg weekly).
(15) Menendez 2008 MOZ: SP (two doses)
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Analysis 1.16. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 16 Cord
blood anaemia.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 16 Cord blood anaemia
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Fleming 1986 NGA (1) 21/50 2/14 100.0 % 2.94 [ 0.78, 11.05 ]
Subtotal (95% CI) 50 14 100.0 % 2.94 [ 0.78, 11.05 ]
Total events: 21 (Intervention), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
2 All women
Menendez 2008 MOZ (2) 22/435 45/435 100.0 % 0.49 [ 0.30, 0.80 ]
Subtotal (95% CI) 435 435 100.0 % 0.49 [ 0.30, 0.80 ]
Total events: 22 (Intervention), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.85 (P = 0.0044)
Test for subgroup differences: Chi2 = 6.20, df = 1 (P = 0.01), I2 =84%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Fleming 1986 NGA: Proguanil 100 mg daily.
(2) Menendez 2008 MOZ: SP (two doses)
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Analysis 1.17. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 17 Cord
blood haemoglobin.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 17 Cord blood haemoglobin
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Para 0-1
Fleming 1986 NGA (1) 50 14 (2.8) 14 15.8 (2.8) 100.0 % -1.80 [ -3.46, -0.14 ]
Subtotal (95% CI) 50 14 100.0 % -1.80 [ -3.46, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
2 All women
Menendez 2008 MOZ (2) 494 45.06 (7.88) 496 44.05 (7.49) 100.0 % 1.01 [ 0.05, 1.97 ]
Subtotal (95% CI) 494 496 100.0 % 1.01 [ 0.05, 1.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Chi2 = 8.26, df = 1 (P = 0.00), I2 =88%
-4 -2 0 2 4
Favours control Favours chemoprevention
(1) Fleming 1986 NGA: Proguanil 100 mg daily. SD approximated
(2) Menendez 2008 MOZ: SP (two doses)
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Analysis 1.18. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 18
Placental parasitemia (fetus).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 18 Placental parasitemia (fetus)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Para 0-1
Menendez 1994 GMB (1) 29/55 45/61 14.6 % 0.71 [ 0.53, 0.96 ]
Cot 1995 CMR (2) 22/56 37/64 12.5 % 0.68 [ 0.46, 1.00 ]
Parise 1998ii KEN (3) 28/316 46/171 11.5 % 0.33 [ 0.21, 0.51 ]
Parise 1998i KEN (4) 36/330 46/171 12.3 % 0.41 [ 0.27, 0.60 ]
Shulman 1999 KEN (5) 16/205 29/196 8.8 % 0.53 [ 0.30, 0.94 ]
Ndyomugyenyi 2000 UGA (6) 54/169 74/168 14.9 % 0.73 [ 0.55, 0.96 ]
Njagi 2003ii KEN 22/148 45/134 11.1 % 0.44 [ 0.28, 0.70 ]
Njagi 2003i KEN 28/172 35/170 11.2 % 0.79 [ 0.50, 1.24 ]
Challis 2004 MOZ (7) 3/124 16/120 3.2 % 0.18 [ 0.05, 0.61 ]
Subtotal (95% CI) 1575 1255 100.0 % 0.54 [ 0.43, 0.69 ]
Total events: 238 (Intervention), 373 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 22.49, df = 8 (P = 0.004); I2 =64%
Test for overall effect: Z = 5.06 (P < 0.00001)
2 All women
Morley 1964 NGA (8) 1/115 18/105 14.8 % 0.05 [ 0.01, 0.37 ]
Cot 1992 BFA (9) 19/463 83/437 28.3 % 0.22 [ 0.13, 0.35 ]
Menendez 2008 MOZ (10) 222/426 219/419 29.9 % 1.00 [ 0.88, 1.13 ]
Ndyomugyenyi 2011 UGA (11) 19/613 16/622 27.0 % 1.20 [ 0.63, 2.32 ]
Subtotal (95% CI) 1617 1583 100.0 % 0.44 [ 0.15, 1.29 ]
Total events: 261 (Intervention), 336 (Control)
Heterogeneity: Tau2 = 1.01; Chi2 = 52.35, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.70), I2 =0.0%
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(1) Menendez 1994 GMB: Pyrimethamine-dapsone 12.5mg/100mg weekly
(2) Cot 1995 CMR: Chloroquine (300mg weekly)
(3) Parise 1998ii KEN: SP (monthly).
(4) Parisse 1998i KEN: SP (two doses).
(5) Shulman 1999 KEN: SP (three doses).
(6) Ndyomugyenyi 2000 UGA: Chloroquine 300mg weekly.
(7) Challis 2004 MOZ: SP (two doses).
(8) Morley 1964 NGA: Pyrimethamine (100mg monthly).
(9) Cot 1992 BFA: Chloroquine (300mg weekly).
(10) Menendez 2008 MOZ: SP (two doses)
(11) Ndyomugyenyi 2011 UGA: SP (two doses).
Analysis 1.19. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 19 Cord
blood parasitaemia.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 19 Cord blood parasitaemia
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Para 0-1
Parise 1998i KEN (1) 9/432 7/236 50.0 % 0.70 [ 0.26, 1.86 ]
Parise 1998ii KEN (2) 3/431 7/236 50.0 % 0.23 [ 0.06, 0.90 ]
Subtotal (95% CI) 863 472 100.0 % 0.47 [ 0.22, 1.01 ]
Total events: 12 (Intervention), 14 (Control)
Heterogeneity: Chi2 = 1.68, df = 1 (P = 0.19); I2 =40%
Test for overall effect: Z = 1.95 (P = 0.052)
2 All women
Ndyomugyenyi 2011 UGA (3) 32/1298 45/1331 100.0 % 0.73 [ 0.47, 1.14 ]
Subtotal (95% CI) 1298 1331 100.0 % 0.73 [ 0.47, 1.14 ]
Total events: 32 (Intervention), 45 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Chi2 = 0.96, df = 1 (P = 0.33), I2 =0.0%
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(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Ndyomugyenyi 2011 UGA: SP (two doses).
Analysis 1.20. Comparison 1 Preventive antimalarials versus placebo/no intervention, Outcome 20 Adverse
effects (baby).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 1 Preventive antimalarials versus placebo/no intervention
Outcome: 20 Adverse effects (baby)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Neonatal icterus
Parise 1998ii KEN (1) 46/331 29/170 48.2 % 0.81 [ 0.53, 1.25 ]
Parise 1998i KEN (2) 49/325 29/170 47.9 % 0.88 [ 0.58, 1.35 ]
Shulman 1999 KEN (3) 2/626 3/611 3.8 % 0.65 [ 0.11, 3.88 ]
Subtotal (95% CI) 1282 951 100.0 % 0.84 [ 0.63, 1.13 ]
Total events: 97 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Congenital anomalies
Nosten 1994 THA (4) 4/159 1/152 66.9 % 3.82 [ 0.43, 33.83 ]
Menendez 2008 MOZ (5) 1/514 0/503 33.1 % 2.94 [ 0.12, 71.90 ]
Subtotal (95% CI) 673 655 100.0 % 3.53 [ 0.58, 21.33 ]
Total events: 5 (Intervention), 1 (Control)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Chi2 = 2.38, df = 1 (P = 0.12), I2 =58%
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(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
(3) Shulman 1999 KEN: SP (three doses).
(4) Nosten 1994 THA: Mefloquine weekly. Mefloquine group: limb dysplasia, ventricular septal defect, amniotic bands; placebo group: anencephaly
(5) Menendez 2008 MOZ: SP (two doses). One major congenital malformation (spina bifida) in SP group
Analysis 2.1. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 1 Death (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 1 Death (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shulman 1999 KEN (1) 1/567 4/564 72.6 % 0.25 [ 0.03, 2.22 ]
Njagi 2003ii KEN (2) 2/193 1/189 18.3 % 1.96 [ 0.18, 21.42 ]
Njagi 2003i KEN (3) 2/207 0/206 9.1 % 4.98 [ 0.24, 103.02 ]
Total (95% CI) 967 959 100.0 % 0.99 [ 0.30, 3.22 ]
Total events: 5 (Intervention), 5 (Control)
Heterogeneity: Chi2 = 2.93, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Not applicable
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Favours Intervention Favours Control
(1) Shulman 1999 KEN: SP (three doses).
(2) Njagi 2003ii KEN: SP (two doses).
(3) Njagi 2003i KEN: SP (two doses) + ITNs
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Analysis 2.2. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 2 Severe anaemia
(mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 2 Severe anaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Parise 1998ii KEN (1) 9/352 10/197 6.8 % 0.50 [ 0.21, 1.22 ]
Parise 1998i KEN (2) 11/365 10/197 7.5 % 0.59 [ 0.26, 1.37 ]
Shulman 1999 KEN (3) 82/567 134/565 85.1 % 0.61 [ 0.48, 0.78 ]
Menendez 2008 MOZ (4) 0/133 3/127 0.6 % 0.14 [ 0.01, 2.62 ]
Total (95% CI) 1417 1086 100.0 % 0.60 [ 0.47, 0.75 ]
Total events: 102 (Intervention), 157 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.43 (P < 0.00001)
Test for subgroup differences: Not applicable
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Favours chemoprevention Favours control
(1) Parisse 1998ii KEN: SP (monthly). Severe anaemia defined as Hb<7 g/dL.
(2) Parisse 1998i KEN: SP (two doses). Severe anaemia defined as Hb<7 g/dL.
(3) Shulman 1999 KEN: SP (three doses). Severe anaemia defined as Hb<8 g/dL
(4) Menendez 2008 MOZ: SP (two doses). Severe anaemia defined as PCV<21%
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Analysis 2.3. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 3 Anaemia (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 3 Anaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Parise 1998ii KEN (1) 275/431 174/236 25.2 % 0.87 [ 0.78, 0.96 ]
Parise 1998i KEN (2) 294/432 174/236 25.9 % 0.92 [ 0.84, 1.02 ]
Shulman 1999 KEN (3) 431/567 460/565 32.8 % 0.93 [ 0.88, 0.99 ]
Njagi 2003ii KEN (4) 51/183 80/175 7.7 % 0.61 [ 0.46, 0.81 ]
Njagi 2003i KEN (5) 67/198 72/196 8.4 % 0.92 [ 0.70, 1.20 ]
Total (95% CI) 1811 1408 100.0 % 0.88 [ 0.81, 0.96 ]
Total events: 1118 (Intervention), 960 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 9.98, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 2.78 (P = 0.0054)
Test for subgroup differences: Not applicable
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Favours chemoprevention Favours control
(1) Parisse 1998ii KEN: SP (monthly). Anaemia defined as Hb≤11 g/dL.
(2) Parisse 1998i KEN: SP (two doses). Anaemia defined as Hb≤11 g/dL.
(3) Shulman 1999 KEN: SP (three doses). Anaemia defined as Hb < 11 g/dL
(4) Njagi 2003ii KEN: SP (two doses). Anaemia defined as Hb<10.0 g/dL
(5) Njagi 2003i KEN: SP (two doses) + ITNs. Anaemia defined as Hb<10.0 g/dL
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Analysis 2.4. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 4 Mean haemoglobin
(g/dL).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 4 Mean haemoglobin (g/dL)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parise 1998ii KEN 352 10.4 (1.8) 197 9.9 (1.7) 19.3 % 0.50 [ 0.20, 0.80 ]
Parise 1998i KEN 365 10.2 (1.7) 197 9.9 (1.7) 20.4 % 0.30 [ 0.01, 0.59 ]
Shulman 1999 KEN (1) 567 9.7 (1.76) 565 9.3 (1.85) 39.9 % 0.40 [ 0.19, 0.61 ]
Njagi 2003i KEN 198 10.8 (2) 196 10.6 (2.1) 10.8 % 0.20 [ -0.21, 0.61 ]
Njagi 2003ii KEN 183 11 (1.9) 175 10.3 (2.2) 9.7 % 0.70 [ 0.27, 1.13 ]
Total (95% CI) 1665 1330 100.0 % 0.41 [ 0.27, 0.54 ]
Heterogeneity: Chi2 = 3.69, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.99 (P < 0.00001)
Test for subgroup differences: Not applicable
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(1) Shulman 1999 KEN: SP (three doses).
101Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.5. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 5 Parasitaemia (mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 5 Parasitaemia (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Parise 1998i KEN (1) 34/348 48/178 14.8 % 0.36 [ 0.24, 0.54 ]
Parise 1998ii KEN (2) 22/327 48/177 14.2 % 0.25 [ 0.16, 0.40 ]
Shulman 1999 KEN (3) 30/567 199/564 15.1 % 0.15 [ 0.10, 0.22 ]
Njagi 2003i KEN (4) 28/172 35/170 14.4 % 0.79 [ 0.50, 1.24 ]
Njagi 2003ii KEN (5) 22/148 45/134 14.3 % 0.44 [ 0.28, 0.70 ]
Challis 2004 MOZ (6) 18/208 40/203 13.7 % 0.44 [ 0.26, 0.74 ]
Menendez 2008 MOZ (7) 18/133 30/127 13.6 % 0.57 [ 0.34, 0.97 ]
Total (95% CI) 1903 1553 100.0 % 0.38 [ 0.24, 0.59 ]
Total events: 172 (Intervention), 445 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 41.68, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 4.26 (P = 0.000021)
Test for subgroup differences: Not applicable
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(1) Parise 1998i KEN: SP (two doses). Parasitemia at delivery
(2) Parise 1998ii KEN: SP (monthly). Parasitaemia at delivery
(3) Shulman 1999 KEN: SP (three doses). Malaria parasitaemia assessed at 34 weeks of gestation
(4) Njagi 2003i KEN: SP (two doses)+ ITNs.
(5) Njagi 2003ii KEN: SP (two doses).
(6) Challis 2004 MOZ: SP (two doses). Parasitaemia measured at the beginning of the third tirmester
(7) Menendez 2008 MOZ: SP (two doses). Parasitaemia at delivery
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Analysis 2.6. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 6 Clinical malaria
(mother).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 6 Clinical malaria (mother)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Challis 2004 MOZ (1) 2/88 8/86 100.0 % 0.24 [ 0.05, 1.12 ]
Total (95% CI) 88 86 100.0 % 0.24 [ 0.05, 1.12 ]
Total events: 2 (Intervention), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
Test for subgroup differences: Not applicable
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Favours chemoprevention Favours control
(1) Challis 2004 MOZ: SP (two doses).
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Analysis 2.7. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 7 Spontaneous abortion.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 7 Spontaneous abortion
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998i KEN (1) 5/432 5/236 15.6 % 0.55 [ 0.16, 1.87 ]
Parise 1998ii KEN (2) 9/431 5/236 15.6 % 0.99 [ 0.33, 2.91 ]
Njagi 2003i KEN (3) 7/207 10/206 24.1 % 0.70 [ 0.27, 1.79 ]
Njagi 2003ii KEN (4) 8/193 13/189 31.6 % 0.60 [ 0.26, 1.42 ]
Challis 2004 MOZ (5) 0/218 5/224 13.1 % 0.09 [ 0.01, 1.68 ]
Total (95% CI) 1481 1091 100.0 % 0.61 [ 0.38, 0.99 ]
Total events: 29 (Intervention), 38 (Control)
Heterogeneity: Chi2 = 2.49, df = 4 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.044)
Test for subgroup differences: Not applicable
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Favours chemoprevention Favours control
(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Njagi 2003i KEN: SP (two doses) + ITNs
(4) Njagi 2003ii KEN: SP (two doses).
(5) Challis 2004 MOZ: SP (two doses).
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Analysis 2.8. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 8 Stillbirth.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 8 Stillbirth
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998i KEN (1) 11/432 5/236 16.5 % 1.20 [ 0.42, 3.42 ]
Parise 1998ii KEN (2) 9/431 5/236 16.5 % 0.99 [ 0.33, 2.91 ]
Shulman 1999 KEN (3) 24/626 26/611 67.1 % 0.90 [ 0.52, 1.55 ]
Total (95% CI) 1489 1083 100.0 % 0.96 [ 0.62, 1.50 ]
Total events: 44 (Intervention), 36 (Control)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
Test for subgroup differences: Not applicable
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Favours chemoprevention Favours control
(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Shulman 1999 KEN: SP (three doses).
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Analysis 2.9. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 9 Perinatal deaths.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 9 Perinatal deaths
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shulman 1999 KEN (1) 39/626 49/611 100.0 % 0.78 [ 0.52, 1.17 ]
Total (95% CI) 626 611 100.0 % 0.78 [ 0.52, 1.17 ]
Total events: 39 (Intervention), 49 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Shulman 1999 KEN: SP (three doses).
Analysis 2.10. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 10 Neonatal and infant
mortality.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 10 Neonatal and infant mortality
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998i KEN (1) 4/306 2/168 7.2 % 1.10 [ 0.20, 5.93 ]
Parise 1998ii KEN (2) 1/327 2/168 7.4 % 0.26 [ 0.02, 2.81 ]
Shulman 1999 KEN (3) 19/602 30/585 85.3 % 0.62 [ 0.35, 1.08 ]
Total (95% CI) 1235 921 100.0 % 0.62 [ 0.37, 1.05 ]
Total events: 24 (Intervention), 34 (Control)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours chemoprevention Favours control
106Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment (Review)
Copyright © 2014 The Authors. The Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Shulman 1999 KEN: SP (three doses).
Analysis 2.11. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 11 Preterm birth.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 11 Preterm birth
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998ii KEN (1) 42/350 22/180 26.6 % 0.98 [ 0.61, 1.59 ]
Parise 1998i KEN (2) 35/341 22/180 26.4 % 0.84 [ 0.51, 1.39 ]
Challis 2004 MOZ (3) 40/218 52/224 47.0 % 0.79 [ 0.55, 1.14 ]
Total (95% CI) 909 584 100.0 % 0.85 [ 0.66, 1.10 ]
Total events: 117 (Intervention), 96 (Control)
Heterogeneity: Chi2 = 0.49, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
(3) Challis 2004 MOZ: SP (two doses).
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Analysis 2.12. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 12 Low birthweight.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 12 Low birthweight
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998ii KEN (1) 26/331 26/170 18.0 % 0.51 [ 0.31, 0.86 ]
Parise 1998i KEN (2) 27/325 26/170 17.8 % 0.54 [ 0.33, 0.90 ]
Njagi 2003i KEN (3) 25/193 22/189 11.6 % 1.11 [ 0.65, 1.90 ]
Njagi 2003ii KEN (4) 21/176 29/170 15.4 % 0.70 [ 0.42, 1.18 ]
Challis 2004 MOZ (5) 19/200 27/203 14.0 % 0.71 [ 0.41, 1.24 ]
Menendez 2008 MOZ (6) 29/133 25/121 13.7 % 1.06 [ 0.66, 1.70 ]
Ndyomugyenyi 2011 UGA (7) 27/333 18/329 9.5 % 1.48 [ 0.83, 2.64 ]
Total (95% CI) 1691 1352 100.0 % 0.81 [ 0.67, 0.99 ]
Total events: 174 (Intervention), 173 (Control)
Heterogeneity: Chi2 = 12.71, df = 6 (P = 0.05); I2 =53%
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
(3) Njagi 2003ii KEN: SP (two doses) + ITNs.
(4) Njagi 2003ii KEN: SP (two doses).
(5) Challis 2004 MOZ: SP (two doses).
(6) Menendez 2008 MOZ: SP (two doses)
(7) Ndyomugyenyi 2011 UGA: SP (two doses).
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Analysis 2.13. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 13 Mean birthweight
(baby).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 13 Mean birthweight (baby)
Study or subgroup Intervention Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parise 1998i KEN (1) 325 3183 (534) 170 3079 (585) 12.7 % 104.00 [ -1.37, 209.37 ]
Parise 1998ii KEN (2) 331 3198 (528) 170 3079 (585) 12.8 % 119.00 [ 14.27, 223.73 ]
Njagi 2003ii KEN (3) 176 2991 (418) 170 2908 (457) 16.5 % 83.00 [ -9.37, 175.37 ]
Njagi 2003i KEN (4) 193 2961 (477) 189 2975 (446) 16.4 % -14.00 [ -106.58, 78.58 ]
Challis 2004 MOZ (5) 200 3077 (533) 203 2926 (494) 13.9 % 151.00 [ 50.63, 251.37 ]
Ndyomugyenyi 2011 UGA (6) 284 3009 (350) 282 2848 (500) 27.7 % 161.00 [ 89.85, 232.15 ]
Total (95% CI) 1509 1184 100.0 % 105.50 [ 68.02, 142.98 ]
Heterogeneity: Chi2 = 9.82, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 5.52 (P < 0.00001)
Test for subgroup differences: Not applicable
-1000 -500 0 500 1000
Favours control Favours chemoprevention
(1) Parisse 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Njagi 2003ii KEN: SP (two doses).
(4) Njagi 2003i KEN: SP (two doses) + ITNs
(5) Challis 2004 MOZ: SP (two doses).
(6) Ndyomugyenyi 2011 UGA: SP (two doses).
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Analysis 2.14. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 14 Placental
parasitemia (fetus).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 14 Placental parasitemia (fetus)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Parise 1998i KEN (1) 36/330 46/171 21.2 % 0.41 [ 0.27, 0.60 ]
Parise 1998ii KEN (2) 28/316 46/171 19.9 % 0.33 [ 0.21, 0.51 ]
Shulman 1999 KEN (3) 16/205 29/196 15.1 % 0.53 [ 0.30, 0.94 ]
Njagi 2003i KEN 28/172 35/170 19.2 % 0.79 [ 0.50, 1.24 ]
Njagi 2003ii KEN 22/148 45/134 19.1 % 0.44 [ 0.28, 0.70 ]
Challis 2004 MOZ (4) 3/124 16/120 5.4 % 0.18 [ 0.05, 0.61 ]
Total (95% CI) 1295 962 100.0 % 0.45 [ 0.33, 0.61 ]
Total events: 133 (Intervention), 217 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 10.79, df = 5 (P = 0.06); I2 =54%
Test for overall effect: Z = 5.13 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours chemoprevention Favours control
(1) Parisse 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Shulman 1999 KEN: SP (three doses).
(4) Challis 2004 MOZ: SP (two doses).
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Analysis 2.15. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 15 Cord blood
parasitaemia.
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 15 Cord blood parasitaemia
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Parise 1998ii KEN (1) 3/431 7/236 50.0 % 0.23 [ 0.06, 0.90 ]
Parise 1998i KEN (2) 9/432 7/236 50.0 % 0.70 [ 0.26, 1.86 ]
Total (95% CI) 863 472 100.0 % 0.47 [ 0.22, 1.01 ]
Total events: 12 (Intervention), 14 (Control)
Heterogeneity: Chi2 = 1.68, df = 1 (P = 0.19); I2 =40%
Test for overall effect: Z = 1.95 (P = 0.052)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Parise 1998ii KEN: SP (monthly).
(2) Parise 1998i KEN: SP (two doses).
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Analysis 2.16. Comparison 2 IPT with SP versus placebo/no intervention, Outcome 16 Adverse effects
(baby).
Review: Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment
Comparison: 2 IPT with SP versus placebo/no intervention
Outcome: 16 Adverse effects (baby)
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Neonatal icterus
Parise 1998i KEN (1) 49/325 29/170 47.6 % 0.88 [ 0.58, 1.35 ]
Parise 1998ii KEN (2) 46/331 29/170 47.9 % 0.81 [ 0.53, 1.25 ]
Shulman 1999 KEN (3) 2/626 3/611 3.8 % 0.65 [ 0.11, 3.88 ]
Subtotal (95% CI) 1282 951 99.4 % 0.84 [ 0.63, 1.13 ]
Total events: 97 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 0.15, df = 2 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Congenital anomalies
Menendez 2008 MOZ (4) 1/514 0/503 0.6 % 2.94 [ 0.12, 71.90 ]
Subtotal (95% CI) 514 503 0.6 % 2.94 [ 0.12, 71.90 ]
Total events: 1 (Intervention), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI) 1796 1454 100.0 % 0.85 [ 0.64, 1.15 ]
Total events: 98 (Intervention), 61 (Control)
Heterogeneity: Chi2 = 0.73, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 0.58, df = 1 (P = 0.45), I2 =0.0%
0.01 0.1 1 10 100
Favours chemoprevention Favours control
(1) Parise 1998i KEN: SP (two doses).
(2) Parise 1998ii KEN: SP (monthly).
(3) Shulman 1999 KEN: SP (three doses).
(4) Menendez 2008 MOZ: SP (two doses). One major congenital malformation (spina bifida) in SP group
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A D D I T I O N A L T A B L E S
Table 1. Optimal information size calculations: Chemoprevention versus placebo
Outcome Assumed risk Source Clinically important relative re-
duction
Sample size required1,2
Maternal mortality 350/100,000 Analysis 1.1 25% 125228
Severe anaemia 150/1000 Analysis 1.2 25% 2540
Anaemia 650/1000 Analysis 1.3 25% 284
Malaria 170/1000 Analysis 1.5 25% 2194
Parasitaemia 290/1000 Analysis 1.6 25% 1124
Spontaneous abortions 32/1000 Analysis 1.9 25% 13348
Still births 33/1000 Analysis 1.10 25% 12932
Neonatal deaths 37/1000 Analysis 1.12 25% 11492
Preterm birth 160/1000 Analysis 1.13 25% 2356
Low birthweight 150/1000 Analysis 1.14 25% 2540
Placental parasitaemia 300/1000 Analysis 1.18 25% 1074
1 All calculations are based on: 2-sided tests, with a ratio of 1:1, power of 0.8, and confidence level of 0.05.
2 All calculations were performed using: http://www.sealedenvelope.com/power/binary-superiority
Table 2. Chloroquine versus placebo (effect on P. vivax malaria)
Outcomes Trials Participants Effect estimate Comment
Death (mother) 1 951 Risk ratio 0.34 (0.01, 8.28) -
Severe anaemia 1 - - Not reported
Anaemia 1 951 Risk ratio 1.00 (0.92, 1.08) Defined as PCV < 30%
Clinical malaria 1 - - Not reported
P. vivax parasitaemia 1 942 Risk ratio 0.01 (0.00, 0.20) History of antenatal parasitaemia. Nine
women censored (they had P.
falciparum infection prior to their first
P. vivax episode)
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Table 2. Chloroquine versus placebo (effect on P. vivax malaria) (Continued)
Adverse effects with
chloroquine
1 951 Risk ratio 2.03 (0.18, 22.31) The 5most commonly reported adverse
events were headache, anorexia,
sleep disorder, dizziness and weakness.
CQ group: drug suspended in two
cases (1 - constipation,1- nausea)
One woman in the placebo group was
complaining of visual problems
Spontaneous abortion 1 951 Risk ratio 0.71 (0.36, 1.39) -
Stillbirth 1 865 Risk ratio 0.24 (0.03, 2.17) -
Perinatal deaths 1 - - Not reported
Neonatal and infant
mortality
1 - - Not reported
Preterm birth (All) 1 733 Risk ratio 0.93 (0.46, 1.85) -
Preterm birth (Para 0) 1 141 Risk ratio 2.41 (0.63, 9.24) -
Preterm birth (Para 2+) 1 592 Risk ratio 0.62 (0.26, 1.46) -
Low birthweight (All) 1 733 Risk ratio 1.02 (0.71, 1.46) -
Lowbirthweight (Para 0) 1 141 Risk ratio 1.20 (0.65, 2.21) -
Low birthweight (Para
2+)
1 592 Risk ratio 0.94 (0.60, 1.47) -
Mean birthweight (All) 1 733 Mean difference -8.20 (-73.41, 57.02) -
Mean birthweight (Para
0)
1 141 Mean difference -36.00 (-188.73, 116.
73)
Mean (SD) 2741 ± 481 versus 2777 ±
435 in the CQ versus placebo group
Mean birthweight (Para
2+)
1 592 Mean difference -2.00 (-74.12, 70.12) Mean (SD) 2954 ± 423 versus 2956 ±
471 in the CQ versus placebo group
Placental malaria 1 - - Not reported
Cord blood haemoglo-
bin
1 - - Not reported
Cord blood parasitaemia 1 - - Not reported
Adverse effects (baby) 1 864 Risk ratio 1.22 (0.33, 4.50) Congenital anomalies: Amniotic band-
ing, brachydactyly; anophthalmia,
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Table 2. Chloroquine versus placebo (effect on P. vivax malaria) (Continued)
Down’s syndrome,; amniotic banding,
absent digit toes; two cleft lip, one cleft
palate in the placebo group
A P P E N D I C E S
Appendix 1. Search methods: detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 malaria MALARIA MALARIA MALARIA malaria
2 pregnan* malaria malaria malaria pregnan*
3 1 and 2 1 or 2 1 or 2 1 or 2 1 and 2
4 - PREGNANCY PREGNANCY PREGNANCY -
5 - pregnan* pregnan* pregnan$ -
6 - 4 or 5 4 or 5 4 or 5 -
7 - 3 and 6 3 and 6 3 and 6 -
8 - - Limit 7 to human Limit 7 to human -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2005); upper case: MeSH or EMTREE heading; lower case: free text term.
Appendix 2. Chemoprophylaxis regimens evaluated in the trials
Chemoprevention regimen Trials
Drug Dose Frequency
Chloroquine 300 mg Weekly Cot 1992 BFA;
Cot 1995 CMR; Ndyomugyenyi 2000 UGA;
Villegas 2007 THA
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(Continued)
Pyrimethamine 100 mg Monthly Morley 1964 NGA
25 mg Weekly Nahlen 1989 NGA
Proguanil 100 mg Daily Fleming 1986 NGA
Pyrimethamine-dapsone 25 mg/100 mg Every two weeks Greenwood 1989 GMB
12.5 mg/100 mg Weekly Menendez 1994 GMB
Sulfadoxine-pyrimethamine 1500 mg/75 mg One to two doses Shulman 1999 KEN
Two doses Challis 2004 MOZ; Menendez 2008 MOZ;
Njagi 2003i KEN; Parise 1998i KEN
Up to four doses Mbaye 2006 GMB
Monthly Parise 1998ii KEN
Mefloquine 500 mg loading dose, 250 mg
weekly for 4 weeks, 125 mg
weekly until delivery
Weekly Nosten 1994 THA
Appendix 3. Trial participants: number of previous pregnancies
No. of pregnancies Trials number of trials
All women Morley 1964 NGA; Nahlen 1989 NGA; Cot
1992 BFA; Nosten 1994 THA; Greenwood 1989
GMB;Villegas 2007THA;Menendez 2008MOZ;
Ndyomugyenyi 2011 UGA;
8
First pregnancy Fleming 1986 NGA; Menendez 1994 GMB; Cot
1995 CMR; Shulman 1999 KEN; Ndyomugyenyi
2000 UGA; Challis 2004 MOZ
6
First or second pregnancy Parise 1998i KEN; Njagi 2003ii KEN 2
Only multiparous women Mbaye 2006 GMB 1
Nahlen 1989 NGA; Greenwood 1989 GMB; Menendez 2008 MOZ all provided data disaggregated by parity.
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Appendix 4. Percentage of randomized participants included in the analyses
Trial Women Newborns
Outcome n/Na % in analysis Outcome n/Na % in analysis
Challis 2004
MOZ
Parasitaemia 411/600 69 Low birthweight 403/600 67
Cot 1992 BFA Placental malaria 904/1464 62 Birthweight 1148/1148 100
Cot 1995 CMR Placental malaria 120/266 57 Birthweight 209/266 79
Fleming 1986
NGA
Haemoglobin 107/200 45 Perinatal death 152/200 76
Greenwood
1989 GMB
Parasitaemia 257/1049 24 Birthweight 877/1034 85
Menendez 1994
GMB
Placental malaria 116/230 50 Birthweight 182/203 90
Morley 1964
NGA
Antenatal para-
sitaemia
227/429 53 Birthweight 429/429 100
Nahlen 1989
NGA
Parasitaemia 71/71 100 - - -
Ndyomugyenyi
2000 UGA
Anaemia 510/860 59 Congenital malaria 337/510 66
Nosten 1994
THA
Parasitaemia 399/399 100 Birthweight 290/290 100
Parise 1998i
KEN, Parise
1998ii KEN
Haemoglobin 1378/2077 66 - - -
Shulman 1999
KEN
Severe anaemia 1132/1264 90 - - -
aNumber analysed/number randomized.
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WH A T ’ S N E W
Last assessed as up-to-date: 1 June 2014.
Date Event Description
29 September 2014 New citation required but conclusions have not
changed
We repeated all searches. Trial inclusion criteria, data
extraction, risk of bias assessment, and data entry were
all done afresh. We additionally carried out GRADE
analysis and a sensitivity analysis of IPT.Contributions
of individuals are outlined in section ’Contributions
of authors’
29 September 2014 New search has been performed Review updated.
H I S T O R Y
Protocol first published: Issue 1, 1995
Review first published: Issue 1, 1995
Date Event Description
16 September 2008 Amended Converted to new review format with minor editing.
20 August 2006 Amended 2006, Issue 4: added Challis 2004 MOZ and Kayentao 2005 MLIa; meta-analysis stratified by
prophylaxis and intermittent preventive treatment; review title shortened
20 November 2002 Amended 2003, Issue 1: Review overhauled to reflect current methods; title was altered to “Drugs for
preventingmalaria-related illness in pregnantwomen anddeath in the newborn” (from“Prevention
versus treatment for malaria in pregnant women”); we excluded mosquito nets as these are now
covered by Gamble 2006; primary outcome measures were adjusted following feedback from
readers; methodological quality of trials reassessed; Martin 1982 trial previously included, but
now excluded because it is not randomized
28 February 2001 Amended Primary outcome measures defined; Parise 1998 trial added.
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C O N T R I B U T I O N S O F A U T H O R S
DR-P re-ran the searches, re-extracted data with PG, updated the risk of bias tables, created GRADE tables, and rewrote the results.
PG assisted with the update, provided advice on the structure and analysis, completed the conceptual framework, checked the GRADE
assessments and revised the results, and wrote the discussion. DS contributed to the GRADE assessment, rewriting the results, and
restructuring the review. KK and FK helped with conceptualising the questions and interpreting the results in context. KK and FK
carefully considered all the included trials and checked for accuracy and completeness. All authors contributed to the final agreed
version of the review.
D E C L A R A T I O N S O F I N T E R E S T
PG is Director of Evidence Building and Synthesis Research Consortium that receives money to increase the number of evidence-
informed decisions by intermediary organizations, including WHO and national decision-makers that benefit the poor in middle- and
low-income countries. DS is employed as part of this Consortium. PG is the coordinator of aWHOCollaborating Centre for Evidence
Synthesis for Infectious and Tropical Diseases (http://apps.who.int/whocc/Detail.aspx?cc˙ref=UNK-234&cc˙code=unk&cc˙contact=
garner&): one of the Centre’s aims is to help WHO in its role as an infomediary in communicating reliable summaries of research
evidence to policy makers, clinicians, teachers, and the public in developing countries.
Feiko ter Kuile is Chief Executive Officer of the Malaria in Pregnancy Consortium, a network of 47 research institutions worldwide
conducting research on the treatment and prevention of malaria in pregnancy, funded by the Bill and Melinda Gates Foundation. He
is principal investigator on several trials investigating intermittent preventive treatment and intermittent screening and treatment in
pregnancy.
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